<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Haloperidol dose for the acute phase of schizophrenia - Donnelly, L - 2013 | Cochrane Library</title> <meta content="Haloperidol dose for the acute phase of schizophrenia - Donnelly, L - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001951.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Haloperidol dose for the acute phase of schizophrenia - Donnelly, L - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001951.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001951.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Haloperidol dose for the acute phase of schizophrenia" name="citation_title"/> <meta content="Lorna Donnelly" name="citation_author"/> <meta content="NHS Lothian" name="citation_author_institution"/> <meta content="lornadonnelly@doctors.org.uk" name="citation_author_email"/> <meta content="John Rathbone" name="citation_author"/> <meta content="The University of Sheffield" name="citation_author_institution"/> <meta content="Clive E Adams" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD001951.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/08/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001951.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001951.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001951.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acute Disease; Antipsychotic Agents [*administration &amp; dosage]; Haloperidol [*administration &amp; dosage]; Randomized Controlled Trials as Topic; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001951.pub2&amp;doi=10.1002/14651858.CD001951.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="jxlIh5Me";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001951\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001951\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001951.pub2",title:"Haloperidol dose for the acute phase of schizophrenia",firstPublishedDate:"Aug 28, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001951.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001951.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001951.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001951.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001951.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001951.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001951.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001951.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001951.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001951.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2514 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001951.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-sec-0174"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-sec-0084"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-sec-0158"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/appendices#CD001951-sec-0185"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/table_n/CD001951StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/table_n/CD001951StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Haloperidol dose for the acute phase of schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information#CD001951-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Lorna Donnelly</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information#CD001951-cr-0003">John Rathbone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information#CD001951-cr-0004">Clive E Adams</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information/en#CD001951-sec-0196">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 August 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001951.pub2">https://doi.org/10.1002/14651858.CD001951.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001951-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001951-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001951-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001951-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001951-abs-0001" lang="en"> <section id="CD001951-sec-0001"> <h3 class="title" id="CD001951-sec-0001">Background</h3> <p>Haloperidol is a benchmark, accessible antipsychotic drug against which the effects of newer treatments are gauged. </p> </section> <section id="CD001951-sec-0002"> <h3 class="title" id="CD001951-sec-0002">Objectives</h3> <p>To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia. </p> </section> <section id="CD001951-sec-0003"> <h3 class="title" id="CD001951-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group Trials Register (February 2010), which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. </p> </section> <section id="CD001951-sec-0004"> <h3 class="title" id="CD001951-sec-0004">Selection criteria</h3> <p>We selected studies if they involved people being treated for acute schizophrenia, randomised to two or more dose ranges of non‐depot haloperidol, and if they reported clinically meaningful outcomes. </p> </section> <section id="CD001951-sec-0005"> <h3 class="title" id="CD001951-sec-0005">Data collection and analysis</h3> <p>For this update, we inspected all citations and independently re‐inspected a sample of citations in order to ensure reliable selection. We resolved any disagreement by discussion, and where doubt remained, we acquired the full‐text article for further inspection. We then ordered papers, and reliably re‐inspected and quality assessed the full reports, and extracted data. For homogeneous dichotomous data, we calculated the risk ratio (RR) with 95% confidence intervals (CI) on an intention‐to‐treat (ITT) basis. We assumed that people who left the study early or were lost to follow‐up had a negative outcome. We calculated mean differences (MD) for continuous outcomes that reported ITT, last observation carried forward (LOCF) data. We excluded data if loss to follow‐up was greater than 50%. </p> </section> <section id="CD001951-sec-0006"> <h3 class="title" id="CD001951-sec-0006">Main results</h3> <p>We included 19 trials with 19 different randomised dose comparisons. No studies reported data on relapse rates or quality of life and only one compared low dose (&gt; 1.5 to 3 mg/day) haloperidol to higher dose ranges. Using standard lower dose (&gt; 3 to 7.5 mg/day) did not result in loss of efficacy (no clinically important improvement in global state, versus standard higher dose (&gt; 7.5 to 15 mg/day, n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.8, <i>very‐low‐quality evidence</i> ); versus high dose (&gt; 15 to 35 mg/day, n = 81, 2 RCTs, RR 0.95, 95% CI 0.8 to 1.2, <i>very‐low‐quality evidence</i> ). Doses of haloperidol in the range of &gt; 3 to 7.5 mg/day had a lower rate of development of clinically significant extrapyramidal adverse effects than higher doses (clinically significant extrapyramidal adverse effects, versus standard higher dose, n = 64, 2 RCTs, RR 0.12, 95% CI 0.01 to 2.1, <i>very‐low‐quality evidence</i> ); versus high dose, n = 144, 3 RCTs, RR 0.59, 95% CI 0.5 to 0.8, very‐low‐quality evidence; versus very high dose (&gt; 35 mg/day, n = 86, 2 RCTs, RR 0.70, 95% CI 0.5 to 1.1, <i>very‐low‐quality evidence</i>). None of the other comparisons between dose ranges yielded statistically significant differences, but several, particularly with lower dose ranges, were underpowered to detect clinically meaningful differences. </p> </section> <section id="CD001951-sec-0007"> <h3 class="title" id="CD001951-sec-0007">Authors' conclusions</h3> <p>Noresults were conclusive and all were based on small, short studies of limited quality. However, it would be understandable if clinicians were cautious in prescribing doses in excess of 7.5 mg/day of haloperidol to a person with uncomplicated acute schizophrenia, and if people with schizophrenia were equally reticent to take greater doses. Further research is needed regarding the efficacy and tolerability of the lower dose ranges, especially &gt; 1.5 to 3 mg/day. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001951-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001951-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001951-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001951-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001951-abs-0003" lang="en"> <h3>Haloperidol dose for the acute phase of schizophrenia</h3> <p>Schizophrenia is a mental illness where the person often experiences both positive symptoms (such as hearing voices, seeing things and having strange beliefs) and negative symptoms (such as tiredness, apathy and loss of emotion). Antipsychotic drugs are used to treat schizophrenia. The antipsychotic drug, haloperidol, is one of the most frequently used drugs worldwide for people with schizophrenia. </p> <p>The benefits of antipsychotic drugs, such as haloperidol, need to be weighed against their tendency for causing debilitating side effects (such as movement disorders, weight gain, lack of drive) and in some cases an increased likelihood of physical illnesses such as diabetes and heart disease. These debilitating side effects may mean that people stop taking their medication, which can lead to relapse and going into hospital. It is, therefore, important to find a tolerable and effective dose of haloperidol, which helps control the symptoms of schizophrenia but with fewer side effects. </p> <p>The main aim of this review was to determine the best range of doses of haloperidol for the treatment of schizophrenia. Nineteen trials were included that compared varying doses of haloperidol. Despite over 30 years of trials, data on the effects of differing doses of haloperidol are sparse and poorly reported. This is especially so for the lower dose ranges generally used for the treatment of schizophrenia today. However, lower doses of haloperidol may be just as effective as higher doses but result in fewer side effects. This review also suggests that an important bias against haloperidol may exist in modern trials comparing new drugs with haloperidol. Results are not conclusive and are based on small, short studies of limited quality. </p> <p>The authors of the review note that it would be understandable if psychiatrists were cautious about prescribing doses above 7.5 mg a day and if people with schizophrenia did not want to take higher dosages. Further research is needed to assess the tolerability and effectiveness of lower doses. Low doses of haloperidol may be just as good as higher doses, but with fewer side effects. </p> <p>This plain language summary was written by a consumer, Benjamin Gray, Service User and Service User Expert. Rethink Mental Illness. Email: <a href="http://mailto:ben.gray@rethink.org" target="_blank"><span class="__cf_email__" data-cfemail="0361666d2d6471627a437166776b6a6d682d6c7164">[email protected]</span></a>. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001951-sec-0174" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001951-sec-0174"></div> <h3 class="title" id="CD001951-sec-0175">Implications for practice</h3> <section id="CD001951-sec-0175"> <p>Almost all data in this review were at modest to high risk of bias. All implications must be tempered with this consideration. </p> <section id="CD001951-sec-0176"> <h5 class="title">1. For clinicians</h5> <p>For people who are acutely ill, there is no evidence of an important drop off in efficacy as the dose of haloperidol declines; this is true to a dose range of &gt; 0.25 to 1.5 mg/day. There are greater numbers of studies examining higher dose ranges and these suggest no clear evidence of advantages of doses greater than the &gt; 3 to 7.5 mg/day range. There is no information on longer‐term outcomes from haloperidol dose studies. </p> <p>Doses above the &gt; 3 to 7.5 mg/day range are associated with increased risk of extrapyramidal adverse effects and probably should be avoided, especially given there is no clear evidence for added efficacy. There are, unfortunately, no data that compare the standard lower dose range (&gt; 3 to 7.5 mg/day) with the next lowest dose range (&gt; 1.5 to 3 mg/day), so it is currently impossible to determine from randomised controlled trials whether there may be added benefit in using even lower dose in terms of the reduction of adverse effects. There are no data regarding long‐term adverse effects, such as rates of tardive dyskinesia, in comparative haloperidol dose trials. </p> <p>This review does not answer the question as to whether there is a dose of haloperidol that may be no different from placebo in terms of extrapyramidal adverse effects or tardive dyskinesia. </p> </section> <section id="CD001951-sec-0177"> <h5 class="title">2. For people with schizophrenia</h5> <p>Generally, there are unlikely to be major benefits from a dose of haloperidol higher than &gt; 3 to 7.5 mg/day for people with schizophrenia. This review cannot answer the question as to whether there may be modest benefits to higher doses, neither can it rule out major benefits of high doses in selected individuals. Doses higher than &gt; 3 to 7.5 mg/day are, however, associated with more extrapyramidal adverse effects. The lowest effective dose of haloperidol during the non‐acute phase of illness is still unknown. People with schizophrenia should note that lack of long‐term data is also a problem with newer antipsychotic agents (<a href="./references#CD001951-bbs2-0064" title="DugganL , FentonM , DardennesRM , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2002</a>; <a href="./references#CD001951-bbs2-0092" title="KennedyE , SongF , HunterR , ClarkeA , GilbodyS . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Kennedy 2002</a>; <a href="./references#CD001951-bbs2-0095" title="LeuchtS , Pitschel‐WalzG , AbrahamD , KisslingW . Efficacy and extra‐pyramidal side‐effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta‐analysis of randomised controlled trials. Schizophrenia Research1999;35:51‐68. ">Leucht 1999</a>; <a href="./references#CD001951-bbs2-0113" title="SrisurapanontM , DisayavanishC , TaimkaewK . Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD000967.pub2] ">Srisurapanont 2002</a>). </p> </section> <section id="CD001951-sec-0178"> <h5 class="title">3. For policy makers</h5> <p>There are no data regarding the impact of varying dose ranges of haloperidol on health service utilisation and costs. </p> <p>This review highlights the need for funding agencies, industry and drug regulatory authorities to collaborate to ensure that clinical trials utilise appropriate dose ranges when comparing new antipsychotic drugs to reference drugs. These agencies should commission or access existing systematic reviews that closely examine dosage issues for reference drugs. They should then ensure that this information is used in the design of clinical trials at the planning stages. Such an intervention would be likely to decrease any real or perceived bias regarding the tolerability and efficacy of new drug agents in the future. This review cannot definitively answer the question as to whether there is a highly tolerable and efficacious dose range of haloperidol that might be an inexpensive equivalent to some of the newer antipsychotic agents. However, it does highlight the possibility that much of the added tolerability attributed to newer drugs is secondary to an inappropriate dosage of haloperidol as a comparator. This issue deserves to be considered when decisions regarding coverage of the new drugs on institutional formularies are being debated. </p> </section> </section> <h3 class="title" id="CD001951-sec-0179">Implications for research</h3> <section id="CD001951-sec-0179"> <section id="CD001951-sec-0180"> <h5 class="title">1. Importance of systematic reviews</h5> <p>This review clearly highlights the importance of systematic reviews for informing research activities. Had this systematic review been completed in 1991, there would have already been 16 studies (nine of these with completer data only ‐ see <a href="./references#CD001951-sec-0204" title="">Characteristics of excluded studies</a>) that reported no significant benefit in randomisation to higher doses of haloperidol for people with acute schizophrenia. Four of these studies involved the standard lower dose range (&gt; 3 to 7.5 mg/day); the earliest study was conducted in 1967. If these results had been incorporated into drug trials of new agents, we would probably have a much clearer idea of the comparative benefits of the newer agents than we do at present. </p> <p>The issue here is not only the matter of publishing studies that address dosage issues, but is also the need for the dissemination of the results of these studies throughout clinical and research practice. Researchers need to work together with funding agencies, the pharmaceutical industry and drug regulatory authorities to ensure that future comparative trials make use of the most up‐to‐date and systematic dosage literature on reference antipsychotic drugs so that future trials are not prone to real or perceived bias related to inappropriate dose comparisons. </p> <p>Cochrane systematic reviews of newer antipsychotic agents have identified six studies that compare new agents with doses of older antipsychotics equivalent to &gt; 3 to 7.5 mg/day of haloperidol, and have a dropout rate of less than 50%. Three involve risperidone (<a href="./references#CD001951-bbs2-0067" title="EmsleyR , McCreadieR , LivingstonM , DeSmedtG , LemmensP . Risperidone in the treatment of first‐episode schizophrenic patients with schizophreniform disorder: a double blind study. Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia. 1995. ">Emsley 1995</a>; <a href="./references#CD001951-bbs2-0079" title="HoybergO , FensboC , RemvigJ , LingJaerdeO , Sloth‐NeilsenM , SalvesenI . Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica1993;88:395‐402. ">Hoyberg 1993</a>; <a href="./references#CD001951-bbs2-0081" title="HuttunenM , PiepponenT , RantanenH , LarmoI , NyholmR , RaitasuoV . Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel group trial. Acta Psychiatrica Scandinavica1995;91:271‐7. ">Huttunen 1995</a>), and three involve quetiapine (<a href="./references#CD001951-bbs2-0094" title="KudoY , NomuraJ , IkawaG , NakajimaT , SaitoM , SakaiT , et al. Clinical trial of quetiapine in schizophrenia‐efficacy and tolerability of quetiapine: a comparative double‐blind study with mosapramine in schizophrenic patients. Proceeding of the Annual Meeting of the World Psychiatric Association; 1999 Aug; Hamburg, Germany. 1999. ">Kudo 1999</a>; <a href="./references#CD001951-bbs2-0104" title="MurasakiM , KoyamaT , YamauchiT , YagiMG , UshijimaS , KamijimaK . Clinical evaluation of quetiapine in schizophrenia‐efficacy and tolerability of quetiapine compared with haloperidol in patients with schizophrenia. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6‐11; Hamburg, Germany. 1999. ">Murasaki 1999</a>; <a href="./references#CD001951-bbs2-0106" title="PeuskensJ , LinkCGG . A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandinavica1997;96:265‐73. ">Peuskens 1997</a>). There are no such studies identified in Cochrane reviews involving ziprasidone or olanzapine (<a href="./references#CD001951-bbs2-0047" title="Bagnall , A‐M.Lewis , RA.Leitner , ML . Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD001945] ">Bagnall 2002</a>; <a href="./references#CD001951-bbs2-0064" title="DugganL , FentonM , DardennesRM , El‐DosokyA , IndranS . Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD001359.pub2] ">Duggan 2002</a>). While the tolerability to the new agents in these studies is generally somewhat higher than to the older drugs, it is much less so than in studies that have utilised high doses of haloperidol as a comparator. In all six studies, the point estimate for the efficacy of the new agent was lower than that of the reference older drug. Thus, the hypothesis that low‐dose haloperidol is an inexpensive equivalent to new antipsychotic agents remains to be excluded. </p> </section> <section id="CD001951-sec-0181"> <h5 class="title">2. The next update</h5> <p>We are aware that this review is repetitive and lists several sets of data twice. For the next update, we will consider only listing each set of data once and directing the reader to other comparisons when relevant. We will also consider using OR rather than RR. We would be interested in the opinion of readers on this point. </p> </section> <section id="CD001951-sec-0182"> <h5 class="title">3. Future studies</h5> <p>Future antipsychotic dose range trials should closely examine outcomes that have been neglected. These include service utilisation, quality of life, satisfaction with treatment and agitation. The latter is particularly important as behavioural agitation may have different dose‐response characteristics than other dimensions of symptoms of schizophrenia. This may partially explain the use of higher doses of neuroleptic agents. We do realise that trial design is something that is to be undertaken with great care and detail, but we suggest an outline for a study that would be most informative and address some of the questions currently unanswered (<a href="#CD001951-tbl-0002">Table 1</a>). </p> <div class="table" id="CD001951-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design for a trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, clearly described, concealed.<br/> Blindness: double, described and tested.<br/> Duration: 8 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia.<br/> N = 450.*<br/> Age: any.<br/> Sex: both.<br/> History: acutely unwell. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Haloperidol 1 mg/day. N = 150.<br/> 2. Haloperidol 2.5 mg/day. N = 150. </p> <p>3. Haloperidol 5 mg/day. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving the study early ‐ reason.</p> <p>Clinical response ‐ no clinically significant response in global state.</p> <p>Extrapyramidal side effects ‐ no clinically significant extrapyramidal side effects, use of anticholinergic medication. </p> <p>Behaviour ‐ agitation, aggression, self harm.</p> <p>Service utilisation ‐ admission, duration of stay.</p> <p>Quality of life ‐ no clinically significant change in quality of life measure.</p> <p>Satisfaction with treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of about 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> </table> </div> <p>Although it would fall beyond the remit of this review, long‐term data on the effects of haloperidol for relapse prevention is also needed. The question of long‐term relapse rates has been given new impetus by the finding that many newer drugs dissociate very quickly from dopamine type 2 (D<sub>2</sub>) receptors in the brain compared to drugs such as haloperidol (<a href="./references#CD001951-bbs2-0090" title="KapurS , SeemanP . Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. American Journal of Psychiatry2001;158(3):360‐9. ">Kapur 2001</a>). It would be useful to know whether treatment with low‐dose haloperidol leads to lower relapse rates compared to new agents in people who take medication intermittently. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001951-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001951-sec-0015"></div> <div class="table" id="CD001951-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DOSES: 2. STANDARD LOWER DOSE (</b> &gt; <b>3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with the acute phase of schizophrenia </p> <p><b>Settings:</b> in hospital </p> <p><b>Intervention:</b> standard lower dose (&gt; 3‐7.5 mg/day) versus other doses </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> STANDARD LOWER DOSE (&gt; 3‐7.5 mg/day) vs. OTHER DOSES</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early (2‐10 weeks) vs. standard higher dose (</b> &gt; <b>7.5‐15 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> <br/> (1 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.12</b> <br/> (0.01 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early (2‐10 weeks) vs. high dose (</b> &gt; <b>15‐35 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.78</b> <br/> (0.47 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>191<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>2,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (120 to 328) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b> <br/> (100 to 271) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. standard higher dose (</b> &gt; <b>7.5‐15 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.09</b> <br/> (0.67 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b> <br/> (375 to 980) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b> <br/> (375 to 980) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (</b> &gt; <b>15‐35 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.75 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>81<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>760 per 1000</b> <br/> (600 to 952) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>828 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>787 per 1000</b> <br/> (621 to 985) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (</b> &gt; <b>7.5‐15 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.12</b> <br/> (0.01 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>64<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> <br/> (1 to 257) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (1 to 170) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (</b> &gt; <b>15‐35 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.59</b> <br/> (0.45 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>144<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>2,4,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>769 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b> <br/> (346 to 600) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>760 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> <br/> (342 to 593) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state/behaviour: clinically significant agitation (2‐10 weeks)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/> (0.69 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>698 per 1000</b> <br/> (517 to 945) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>698 per 1000</b> <br/> (517 to 945) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Limitations in design: rated as 'serious' ‐ no trial described randomisation process or tested blinding. </p> <p><sup>2</sup> Imprecision: rated as 'serious' ‐ very small trials. </p> <p><sup>3</sup> Publication bias: rated as 'serious' ‐ two very small trials. </p> <p><sup>4</sup> Limitations in design: rated as 'serious' ‐ no trial described randomisation process and only one tested blinding informally and found it to be ineffective. </p> <p><sup>5</sup> Publication bias: rated as 'serious' ‐ four small trials. </p> <p><sup>6</sup> Imprecision: rated as 'serious' ‐ single small trial. </p> <p><sup>7</sup> Publication bias: rated as 'serious' ‐ single trial. </p> <p><sup>8</sup> Publication bias: rated as 'serious' ‐ three very small trials. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001951-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001951-sec-0016"></div> <p>Antipsychotic medications are a mainstay of treatment for people with acute schizophrenia. These compounds are beneficial in the short to medium term course of the illness. For example, in a review of 45 randomised studies involving the oldest neuroleptic, chlorpromazine, there was a clinically significant reduction in a person's symptoms over placebo after six months of treatment (10 RCTs, n = 1123, RR 0.76, 95% CI 0.7 to 0.8) (<a href="./references#CD001951-bbs2-0114" title="ThornleyB , AdamsCE , AwadG . Chlorpromazine versus placebo for those with schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD000284.pub2] ">Thornley 2002</a>). When haloperidol was compared with placebo, the findings were similar (8 RCTs, n = 313, RR 0.65, 95% CI 0.6 to 0.8) (<a href="./references#CD001951-bbs2-0085" title="JoyC , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD003082.pub2] ">Joy 2002</a>). The value of these drugs for treating people with acute psychoses needs to be weighed against their tendency to induce significant adverse effects. In one chlorpromazine review, the risk of medication‐related parkinsonism, such as tremor and stiffness, was significantly higher than placebo (10 RCTs, n = 1265, RR 2.0, 95% CI 1.5 to 2.7, NNTH 10, 95% CI 8 to 16) (<a href="./references#CD001951-bbs2-0114" title="ThornleyB , AdamsCE , AwadG . Chlorpromazine versus placebo for those with schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD000284.pub2] ">Thornley 2002</a>). This was also the case in one haloperidol review (4 RCTs, n = 165, RR 8.9, 95% CI 2.6 to 31, NNTH 3, 95% CI 2 to 5) (<a href="./references#CD001951-bbs2-0085" title="JoyC , LawrieS . Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD003082.pub2] ">Joy 2002</a>). Such adverse effects are a cause for concern to people with schizophrenia and their clinicians. </p> <p>Intolerable effects can lead to the premature discontinuation of drugs and result in an increase in potentially damaging relapses of acute symptoms of schizophrenia (<a href="./references#CD001951-bbs2-0074" title="HansenTE , CaseyDE , HoffmanWF . Neuroleptic intolerance. Schizophrenia Bulletin1997;23(4):567‐82. ">Hansen 1997</a>; <a href="./references#CD001951-bbs2-0100" title="MarderSR . Facilitating compliance with antipsychotic medication. Journal of Clinical Psychiatry1998;59(Suppl 3):21‐5. ">Marder 1998</a>). Therefore, various means of minimising adverse effects have been sought (<a href="./references#CD001951-bbs2-0051" title="Bezchlibnyk‐ButlerKZ , RemingtonGJ . Antiparkinsonian drugs in the treatment of neuroleptic‐induced extrapyramidal symptoms. Canadian Journal of Psychiatry1994;39(2):74‐84. ">Bezchlibnyk 1994</a>; <a href="./references#CD001951-bbs2-0060" title="DeOliveiraIR , DeSenaEP , PereiraEL . Haloperidol blood levels and clinical outcome: a meta‐analysis of studies relevant to testing the therapeutic window hypothesis. Journal of Clinical Pharmacy and Therapeutics1996;21(4):229‐36. ">De Oliveira 1996</a>; <a href="./references#CD001951-bbs2-0095" title="LeuchtS , Pitschel‐WalzG , AbrahamD , KisslingW . Efficacy and extra‐pyramidal side‐effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta‐analysis of randomised controlled trials. Schizophrenia Research1999;35:51‐68. ">Leucht 1999</a>; <a href="./references#CD001951-bbs2-0009" title="McEvoyJP , HogartyGE , SteingardS . Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold. Archives of General Psychiatry1991;48(8):739‐45. McEvoyJP , SchoolerNR , WilsonWH . Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin1991;27(2):97‐101. ">McEvoy 1991</a>). The focus of this review will be one specific means of avoiding adverse effects, the determination of a tolerable yet effective dose range of a specific drug. This is often termed the dose‐response relationship (<a href="./references#CD001951-bbs2-0102" title="MillerR . Dose‐response relationships for the antipsychotic effects and parkinsonian side‐effects of typical neuroleptic drugs: practical and theoretical implications. Progress in Neuro‐Psychopharmacology and Biological Psychiatry1997;21(7):1059‐94. ">Miller 1997</a>). We have also chosen to focus this review on a specific antipsychotic agent, haloperidol, which continues to be among the most frequently used drugs for people with schizophrenia worldwide (<a href="./references#CD001951-bbs2-0050" title="BaldessariniRJ , KandoJC , CentorrinoF . Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. American Journal of Psychiatry1995;152(7):1038‐44. ">Baldessarini 1995</a>; <a href="./references#CD001951-bbs2-0084" title="JohnsonRE , McFarlandBH . Antipsychotic drug exposure in a health maintenance organization. Medical Care1993;31(5):432‐44. ">Johnson 1993</a>; <a href="./references#CD001951-bbs2-0093" title="KiivetRA , LlerenaA , DahlML , RootslaneL , Sánchez VegaJ , EklundhT , et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. British Journal of Clinical Pharmacology1995;40(5):467‐76. ">Kiivet 1995</a>; <a href="./references#CD001951-bbs2-0107" title="RaschettiR , Spila AlegianiS , DianaG , DaCasR , TraversaG , PasquiniP . Antipsychotic drug prescription in general practice in Italy. Acta Psychiatrica Scandinavica1993;87(5):317‐21. ">Raschetti 1993</a>; <a href="./references#CD001951-bbs2-0119" title="WilliamsCL , JohnstoneBM , KestersonJG , JavorKA , SchmetzerAD . Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Medical Care1999;37 Suppl 4:81‐6. ">Williams 1999</a>) and haloperidol remains a comparison agent of choice for clinical drug trials of novel agents (<a href="./references#CD001951-bbs2-0045" title="AwadAG . Methodological and design issues in clinical trials of new neuroleptics: an overview. British Journal of Psychiatry1993;Suppl 22:51‐7. ">Awad 1993</a>; <a href="./references#CD001951-bbs2-0115" title="ThornleyB , AdamsCE . Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ1998;317(7167):1181‐4. ">Thornley 1998</a>). </p> <p>The development of the so‐called second‐generation antipsychotics has changed how schizophrenia is treated. Studies have shown these drugs to be a heterogeneous group (<a href="./references#CD001951-bbs2-0059" title="DavisJM , ChenN , GlickID . A meta‐analysis of the efficacy of second‐generation antipsychotics. Archives General Psychiatry2003;60(6):553‐64. ">Davis 2003</a>; <a href="./references#CD001951-bbs2-0069" title="GardnerDM , BaldessariniRJ , WaraichP . Modern antipsychotic drugs: a critical overview. CMAJ2005;172(13):1703‐11. ">Gardner 2005</a>). Clozapine, amisulpride, risperidone and olanzapine antipsychotics are more efficacious than first‐generation antipsychotics and produce a better functional recovery making them cost effective (<a href="./references#CD001951-bbs2-0059" title="DavisJM , ChenN , GlickID . A meta‐analysis of the efficacy of second‐generation antipsychotics. Archives General Psychiatry2003;60(6):553‐64. ">Davis 2003</a>). A lesser propensity to cause extrapyramidal side effects is another benefit of second‐generation over first‐generation drugs, but this must be balanced against metabolic, endocrine and cardiovascular effects (<a href="./references#CD001951-bbs2-0069" title="GardnerDM , BaldessariniRJ , WaraichP . Modern antipsychotic drugs: a critical overview. CMAJ2005;172(13):1703‐11. ">Gardner 2005</a>). </p> <section id="CD001951-sec-0017"> <h3 class="title" id="CD001951-sec-0017">Description of the condition</h3> <p>Schizophrenia is a chronic, relapsing mental illness and has a worldwide lifetime prevalence of about 1% irrespective of culture, social class and race. The acute phase of schizophrenia is the florid psychotic phase, during which the patient exhibits acute symptoms that can include positive symptoms (such as delusions, hallucinations, disorganised thinking and speech), or more profound negative symptoms (such as flattened affect, alogia and avolition), or both positive and negative symptoms. Twenty‐five per cent of those who have experienced an episode of schizophrenia recover and the illness does not recur. Another 25% experience an unremitting illness. Fifty per cent do have a recurrent illness but with long episodes of considerable recovery from the positive symptoms. Current medication is effective in reducing positive symptoms, but negative symptoms are fairly resistant to treatment. In addition, drug treatments are associated with adverse effects and the overall cost of the illness to the individual, their carers and the community is considerable. </p> </section> <section id="CD001951-sec-0018"> <h3 class="title" id="CD001951-sec-0018">Description of the intervention</h3> <p>Haloperidol is a 'typical' or 'older‐generation' antipsychotic. It is a butyrophenone derivative. It was discovered by Paul Janssen and developed by Janssen Pharmaceuticals in Belgium in 1958; however, it was not approved for use in the US until 1967. Haloperidol remains a widely used antipsychotic although the development of 'atypical' antipsychotic agents has seen a decrease in its use in developed countries. It is only one of three antipsychotic drugs on the World Health Organizations Essential Drug List (<a href="./references#CD001951-bbs2-0118" title="World Health Organization. WHO Model Lists of Essential Medicines, 2011 www.who.int/medicines/publications/essentialmedicines/en/. (accessed 20 June 2013). ">WHO 2011</a>). </p> </section> <section id="CD001951-sec-0019"> <h3 class="title" id="CD001951-sec-0019">How the intervention might work</h3> <p>The mechanism of action of haloperidol is not entirely understood but it is thought that its high affinity for the D<sub>2</sub> subtype of dopamine receptor in the mesocortex and limbic systems of the brain is responsible for its efficacy in treating positive symptoms of schizophrenia. There is a marked tendency to produce extrapyramidal effects, which is thought to be due to its antidopaminergic action in the nigrostriatal pathways. </p> <p>Haloperidol has relatively minor antihistamine and anticholinergic properties. It has strong sedative properties. The peripheral actions of haloperidol are thought to be responsible for its antiemetic properties and its potential to cause hyperprolactinaemia. </p> </section> <section id="CD001951-sec-0020"> <h3 class="title" id="CD001951-sec-0020">Why it is important to do this review</h3> <p>There are already important reviews that pool data on the combined dose‐response relationship of various typical antipsychotic agents and that incorporate some data on haloperidol. One review proposed an optimum dosage range of 10 to 15 mg/day haloperidol or the equivalent of such a dose when using other antipsychotics (<a href="./references#CD001951-bbs2-0049" title="BaldessariniRJ , CohenBM , TeicherMH . Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Archives of General Psychiatry1988;45:79‐91. ">Baldessarini 1988</a>). This review summarised randomised controlled trial data combined with information from studies using other methodologies. Another systematic review looking at antipsychotic neuroleptic dose for maintenance management of people with schizophrenia employed systematic review techniques and examined data from randomised controlled trials up to June 1989 (<a href="./references#CD001951-bbs2-0054" title="BolliniP , PampallonaS , OrzaMJ , AdamasME , ChalmersTC . Antipsychotic drugs: is more worse? A meta‐analysis of the published randomised control trials. Psychological Medicine1994;24:307‐16. ">Bollini 1994</a>). The conclusion reached was that there was no benefit from using doses higher than 375 mg/day of chlorpromazine or the equivalent of such a dose when using other antipsychotics (about 7.5 mg/day of haloperidol). </p> <p>There are several reasons for a study to complement this previous work. First, previous reviews need to be updated with data from more recent trials. Second, the use of conversion factors to pool data from studies of different antipsychotics is not based on rigorous evidence and different means of comparing drugs are currently in evolution (<a href="./references#CD001951-bbs2-0045" title="AwadAG . Methodological and design issues in clinical trials of new neuroleptics: an overview. British Journal of Psychiatry1993;Suppl 22:51‐7. ">Awad 1993</a>; <a href="./references#CD001951-bbs2-0086" title="KaneJM . Schizophrenia. New England Journal of Medicine1996;334(1):34‐41. ">Kane 1996</a>; <a href="./references#CD001951-bbs2-0089" title="KapurS . A new framework for investigating antipsychotic action in humans: lessons from pet imaging. Molecular Psychiatry1998;3(2):135‐40. ">Kapur 1998</a>). Thus, this review summarises data from trials investigating the dose‐response relationship of haloperidol alone. Third, several new agents have been developed that are not significantly different from placebo with regard to important adverse effects such as parkinsonism (<a href="./references#CD001951-bbs2-0095" title="LeuchtS , Pitschel‐WalzG , AbrahamD , KisslingW . Efficacy and extra‐pyramidal side‐effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta‐analysis of randomised controlled trials. Schizophrenia Research1999;35:51‐68. ">Leucht 1999</a>). This has led to the recommendation of these agents as first‐line treatments for acute schizophrenia (<a href="./references#CD001951-bbs2-0044" title="American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry1997;154 Suppl 4:1‐63. ">APA 1997</a>; <a href="./references#CD001951-bbs2-0058" title="Canadian Psychiatric Association. Canadian clinical practice guidelines for the treatment of schizophrenia. Canadian Journal of Psychiatry‐Revue Canadienne De Psychiatrie1998;2 Suppl 43:25‐40. ">CPA 1998</a>). Using the cost of mean clinical doses as a basis for comparison, these novel drugs have the drawback of being significantly more expensive than agents such as haloperidol (<a href="./references#CD001951-bbs2-0046" title="AwadAG , VorugantiLP . Cost‐utility analysis in schizophrenia. Journal of Clinical Psychiatry1999;60 Suppl 3:22‐6. ">Awad 1999</a>; <a href="./references#CD001951-bbs2-0071" title="GlazerWM . Formulary decisions and health economics. Journal of Clinical Psychiatry1998;59 Suppl 19:23‐9. ">Glazer 1998</a>; <a href="./references#CD001951-bbs2-0120" title="ZitoJM . Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatric Clinics of North America1998;21(1):181‐202. ">Zito 1998</a>). There is need for a systematic review to determine whether an optimum dosage of the less costly drugs may minimise adverse effects with no significant decrease in clinical efficacy. Finally, many trials of novel agents do not report a clear justification for the dose of reference drug that they choose. They have frequently used doses well in excess of the maximum levels recommended by <a href="./references#CD001951-bbs2-0054" title="BolliniP , PampallonaS , OrzaMJ , AdamasME , ChalmersTC . Antipsychotic drugs: is more worse? A meta‐analysis of the published randomised control trials. Psychological Medicine1994;24:307‐16. ">Bollini 1994</a> and <a href="./references#CD001951-bbs2-0050" title="BaldessariniRJ , KandoJC , CentorrinoF . Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. American Journal of Psychiatry1995;152(7):1038‐44. ">Baldessarini 1995</a>. Using a higher dose of the reference drug, frequently haloperidol, may have biased results in favour of the novel agent due to differential attrition or the promotion of adverse effects in the control arm of the study (<a href="./references#CD001951-bbs2-0045" title="AwadAG . Methodological and design issues in clinical trials of new neuroleptics: an overview. British Journal of Psychiatry1993;Suppl 22:51‐7. ">Awad 1993</a>; <a href="./references#CD001951-bbs2-0083" title="JadadA . Meta‐analysis making the same mistakes as trials. Proceedings of the 2nd Symposium on Systematic Reviews: Beyond the Basics; 1999 Jan 5‐7; Oxford, UK. 1999. ">Jadad 1999</a>). An accurate estimate of a dose range for specific reference drugs that defines an optimum balance between adverse effects and efficacy is urgently needed to serve as a 'gold standard' for future comparative studies. Haloperidol continues to be used as a comparative agent in trials of novel antipsychotics such as lurasidone (<a href="./references#CD001951-bbs2-0055" title="CitromeL . Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved antipsychotic. International Journal of Clinical Practise2011;65(2):189‐210. ">Citrome 2011</a>). </p> <p>Once a decision had been made to undertake a review focusing on the dose‐response of haloperidol, it was important for the review authors to define specific dose ranges to be used. The review authors selected dose ranges (&gt; 0.25 to 1.5 mg/day, &gt; 1.5 to 3 mg/day, &gt; 3 to 7.5 mg/day, &gt; 7.5 to 15 mg/day, &gt; 15 to 35 mg/day and &gt; 35 mg/day) that were considered to reflect patterns of clinical use (<a href="./references#CD001951-bbs2-0048" title="BaldessariniRJ , KatzB , CottonP . Dissimilar dosing with high‐potency and low‐potency neuroleptics. American Journal of Psychiatry1984;141(6):748‐52. ">Baldessarini 1984</a>; <a href="./references#CD001951-bbs2-0108" title="ReardonGT , RifkinA , SchwartzA , MyersonA , SirisSG . Changing patterns of neuroleptic dosage over a decade. American Journal of Psychiatry1989;146(6):726‐9. ">Reardon 1989</a>), research using positron emission tomography (PET) studies (<a href="./references#CD001951-bbs2-0087" title="KapurS , RemingtonG , JonesC , WilsonA , DaSilvaJ , HouleS , et al. High levels of dopamine D2 receptor occupancy with low‐dose haloperidol treatment: a PET study. American Journal of Psychiatry1996;153(7):948‐50. ">Kapur 1996</a>; <a href="./references#CD001951-bbs2-0088" title="KapurS , ZipurskyR , RemingtonG , JonesC , McKayG , HouleS . PET evidence that loxapine is an equipotent blocker of 5‐HT2 and D2 receptors: implications for the therapeutics of schizophrenia. American Journal of Psychiatry1997;154(11):1525‐9. ">Kapur 1997</a>; <a href="./references#CD001951-bbs2-0089" title="KapurS . A new framework for investigating antipsychotic action in humans: lessons from pet imaging. Molecular Psychiatry1998;3(2):135‐40. ">Kapur 1998</a>), the findings of previous reviews (<a href="./references#CD001951-bbs2-0049" title="BaldessariniRJ , CohenBM , TeicherMH . Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Archives of General Psychiatry1988;45:79‐91. ">Baldessarini 1988</a>; <a href="./references#CD001951-bbs2-0054" title="BolliniP , PampallonaS , OrzaMJ , AdamasME , ChalmersTC . Antipsychotic drugs: is more worse? A meta‐analysis of the published randomised control trials. Psychological Medicine1994;24:307‐16. ">Bollini 1994</a>; <a href="./references#CD001951-bbs2-0095" title="LeuchtS , Pitschel‐WalzG , AbrahamD , KisslingW . Efficacy and extra‐pyramidal side‐effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta‐analysis of randomised controlled trials. Schizophrenia Research1999;35:51‐68. ">Leucht 1999</a>), and the recommendations of treatment guidelines (<a href="./references#CD001951-bbs2-0070" title="GeddesJ . Royal College of Psychiatrists guidelines on for the care of those with schizophrenia. The Schizophrenia Trials Meeting; 1999 May 5‐7; Stratford‐upon‐Avon, UK1999. ">Geddes 1999</a>). This review also investigates only within‐study comparisons ‐ where one group of participants has been randomised to two or more dose ranges ‐ and not cross‐study comparisons. In cross‐study comparisons, many variables, such as participant group or clinical setting, may be so radically different as to make comparison fraught with difficulty. </p> <p>Having underlined the need to review a specific drug in predefined dose ranges using multiple dose studies only, the final major factor to discuss was duration of treatment. The review authors did not consider that pooling data where treatment can vary from less than 24 hours' duration to more than six months' duration was justifiable. It has been well established that the efficacy and rate of adverse effects with antipsychotic drugs vary depending on the treatment duration (<a href="./references#CD001951-bbs2-0057" title="ConleyRR , CarpenterWTJr , TammingaCA . Time to clozapine response in a standardized trial. American Journal of Psychiatry1997;154(9):1243‐7. ">Conley 1997</a>; <a href="./references#CD001951-bbs2-0086" title="KaneJM . Schizophrenia. New England Journal of Medicine1996;334(1):34‐41. ">Kane 1996</a>). Therefore, the review authors defined four treatment durations (3 days to &lt; 2 weeks, 2 weeks to 10 weeks, &gt; 10 weeks to 6 months, &gt; 6 months) to reflect various findings on the course of treatment response (<a href="./references#CD001951-bbs2-0027" title="GarverDL , KellyK , FriedKA , MagnussonM , HirschowitzJ . Drug response patterns as a basis of nosology for the mood‐incongruent psychoses (the schizophrenias). Psychological Medicine1988;18:873‐85. MavroidisML , GarverDL , KanterDR , HirschowitzJ . Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacology Bulletin1985;21(1):62‐5. [MEDLINE: 3983340] MavroidisML , KanterDR , HirschowitzJ , GarverDL . Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology1983;81(4):354‐6. ">Garver 1984</a>; <a href="./references#CD001951-bbs2-0077" title="HogartyGE , GoldbergSC . Drug and sociotherapy in the aftercare of schizophrenic patients. One‐year relapse rates. Archives of General Psychiatry1973;28(1):54‐64. ">Hogarty 1973</a>; <a href="./references#CD001951-bbs2-0078" title="HogartyGE , GoldbergSC , SchoolerNR , UlrichRF . Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two‐year relapse rates. Archives of General Psychiatry1974;31(5):603‐8. ">Hogarty 1974</a>; <a href="./references#CD001951-bbs2-0098" title="LevyRH . Sedation in acute and chronic agitation. Pharmacotherapy1996;6(Part 2):152‐9S, 166‐8S. ">Levy 1996</a>; <a href="./references#CD001951-bbs2-0099" title="LiebermanJ , JodyD , GeislerS . Time course and biologic correlates of treatment response in first‐episode schizophrenia. Archives of General Psychiatry1993;50(5):369‐76. ">Lieberman 1993</a>; <a href="./references#CD001951-bbs2-0103" title="MiltonGV , JannMW . Emergency treatment of psychotic symptoms. Pharmacokinetic considerations for antipsychotic drugs. Clinical Pharmacokinetics1995;28(6):494‐504. ">Milton 1995</a>). </p> <p>Several factors may affect results of a review that uses data from trials conducted across a wide time span in many different settings. Variables such as participant age, sex and phase of illness, may substantially differ between studies and affect the size or even direction of outcomes. As diagnostic criteria for schizophrenia have varied over the years (<a href="./references#CD001951-bbs2-0045" title="AwadAG . Methodological and design issues in clinical trials of new neuroleptics: an overview. British Journal of Psychiatry1993;Suppl 22:51‐7. ">Awad 1993</a>), a sensitivity analysis for only the primary outcomes (see <a href="#CD001951-sec-0029">Types of outcome measures</a>) was performed for whether formal diagnostic criteria were used or not. The review authors also performed sensitivity analysis for studies whose participants had schizophrenia defined as first episode or treatment resistant to determine if they differed in their treatment response from other people with schizophrenia. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001951-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001951-sec-0021"></div> <p>To determine the dose‐response relationships for haloperidol, at a range of treatment durations, in the treatment of people with schizophrenia experiencing an acute phase of their illness. </p> <p>It was also proposed to see if:<br/> 1. people whose illnesses were diagnosed using operational criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the International Classification of Diseases (ICD), differed in their treatment response from people with informally derived diagnoses; </p> <p>2. people whose illness was defined as first episode or treatment resistant differed in their treatment response from other people with schizophrenia. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001951-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001951-sec-0022"></div> <section id="CD001951-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001951-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials. We included any trials that were described as 'double‐blind' where it was implied that the studies were randomised and the demographic details of each group were similar. We excluded quasi‐randomised studies, such as those allocated by using alternate days of the week. The duration of studies included in this review needed to be a minimum of three days. </p> </section> <section id="CD001951-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included people with schizophrenia or similar serious, non‐affective psychosis diagnosed by any criteria irrespective of gender, age, or race. If a trial included people with other mental illnesses, we accepted it for inclusion if greater than 50% of participants had serious functional psychotic illnesses such as schizophrenia, but we excluded studies if greater than 33% of people were experiencing an affective psychosis. We considered people to be in the acute phase of schizophrenia if they were experiencing an exacerbation in their baseline level of symptoms, or if they had active symptoms and were currently hospitalised. We excluded studies where greater than 50% of people were considered to be healthy, or were described as undergoing maintenance, or dose reduction treatment. </p> </section> <section id="CD001951-sec-0026"> <h4 class="title">Types of interventions</h4> <section id="CD001951-sec-0027"> <h5 class="title">Drug dosages</h5> <p>1. Haloperidol: dose greater than 0.25 mg/day to 1.5 mg/day (ultra low dose).<br/> 2. Haloperidol: dose greater than 1.5 mg/day to 3 mg/day (low dose).<br/> 3. Haloperidol: dose greater than 3 mg/day to 7.5 mg/day (standard lower dose).<br/> 4. Haloperidol: dose greater than 7.5 mg/day to 15 mg/day (standard higher dose).<br/> 5. Haloperidol: dose greater than 15 mg/day to 35 mg/day (high dose).<br/> 6. Haloperidol: dose greater than 35 mg/day (very high dose). </p> </section> <section id="CD001951-sec-0028"> <h5 class="title">Plasma levels</h5> <p>1. Haloperidol: plasma level greater than 1.4 to 3.5 ng/mL (very low plasma levels).<br/> 2. Haloperidol: plasma level greater than 3.5 to 7 ng/mL (low plasma levels).<br/> 3. Haloperidol: plasma level greater than 7.0 to 16.5 ng/mL (medium plasma levels).<br/> 4. Haloperidol: plasma level greater than 16.5 ng/mL (high plasma levels). </p> <p>We included any means of administration with the exception of depot.</p> </section> </section> <section id="CD001951-sec-0029"> <h4 class="title">Types of outcome measures</h4> <p>We divided outcomes into the following time periods:</p> <p> <ul id="CD001951-list-0001"> <li> <p>three days to less than two weeks;</p> </li> <li> <p>two weeks to 10 weeks *</p> </li> <li> <p>greater than 10 weeks to six months;</p> </li> <li> <p>greater than six months.</p> </li> </ul> </p> <p>* (timescale for primary outcomes of interest)</p> <p>If data on more than one time point within these time periods were available, we used the duration closest to the middle of the time period. For the greater than six months period, we used the longest available time period. </p> <section id="CD001951-sec-0030"> <h5 class="title">Primary outcomes</h5> <section id="CD001951-sec-0031"> <h6 class="title">1. Leaving the study early</h6> </section> <section id="CD001951-sec-0032"> <h6 class="title">2. Clinical response</h6> <p>2.1 No clinically significant response in global state</p> </section> <section id="CD001951-sec-0033"> <h6 class="title">3. Extrapyramidal adverse effects</h6> <p>3.1 No clinically significant extrapyramidal adverse effects</p> </section> <section id="CD001951-sec-0034"> <h6 class="title">4. Behaviour</h6> <p>4.1 Clinically significant agitation</p> </section> </section> <section id="CD001951-sec-0035"> <h5 class="title">Secondary outcomes</h5> <section id="CD001951-sec-0036"> <h6 class="title">1. Mortality, any cause</h6> </section> <section id="CD001951-sec-0037"> <h6 class="title">2. Clinical response</h6> <p>2.1 Mean score/change in global state<br/> 2.2 Clinically significant change in mental state<br/> 2.3 No clinically significant response in psychotic symptoms<br/> 2.4 Mean score/change in psychotic symptoms<br/> 2.5 No clinically significant response in positive symptoms<br/> 2.6 Mean score/change in positive symptoms<br/> 2.7 No clinically significant response in negative symptoms<br/> 2.8 Mean score/change in negative symptoms<br/> 2.9 Relapse </p> </section> <section id="CD001951-sec-0038"> <h6 class="title">3. Extrapyramidal adverse effects</h6> <p>3.1 Use of any antiparkinsonism drugs<br/> 3.2 Mean score/change in extrapyramidal adverse effects<br/> 3.3 Tardive dyskinesia<br/> 3.4 Acute dystonia<br/> 3.5 Akathisia </p> </section> <section id="CD001951-sec-0039"> <h6 class="title">4. Other adverse effects, general and specific</h6> </section> <section id="CD001951-sec-0040"> <h6 class="title">5. Hospital and service utilisation outcomes</h6> <p>5.1 Hospital admission<br/> 5.2 Mean change in days in hospital<br/> 5.3 Improvement in hospital status (e.g. change from formal to informal admission status, use of seclusion, level of observation) </p> </section> <section id="CD001951-sec-0041"> <h6 class="title">6. Economic outcomes</h6> <p>6.1 Mean change in total cost of medical and mental health care<br/> 6.2 Total indirect and direct costs </p> </section> <section id="CD001951-sec-0042"> <h6 class="title">7. Quality of life/satisfaction with care for either recipients of care or carers</h6> <p>7.1. No significant change in quality of life/satisfaction<br/> 7.2 Mean score/change in quality of life/satisfaction </p> </section> <section id="CD001951-sec-0043"> <h6 class="title">8. Behaviour</h6> <p>8.1 Use of adjunctive medication for sedation<br/> 8.2 Aggression to self or others </p> </section> <section id="CD001951-sec-0044"> <h6 class="title">9. Cognitive response</h6> <p>9.1 No clinically important change<br/> 9.2 No change, general and specific </p> </section> </section> </section> </section> <section id="CD001951-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001951-sec-0046"> <h4 class="title">Electronic searches</h4> <section id="CD001951-sec-0047"> <h5 class="title">1. Cochrane Schizophrenia Group Trials Register</h5> <p>The Trials Search Co‐ordinator of the Cochrane Schizophrenia Group searched the Cochrane Schizophrenia Group Trials Register (February 2010) with the phrase:<br/> <br/> [(*dosage‐effect* or *dose‐activity* or *dose‐dependence* or *dose‐effect* or *dose‐rate* or *dose‐response* or *dosage‐scheme* or *drug‐response* or *effective‐dose* or *dose‐finding* or *dose‐calculation* or *therapeutic‐equivalency* or *blood‐level* or *blood‐drug* or *serum‐level* or *serum‐drug* or *plasma‐level* or *plasma‐drug* or *high‐dos* or *low‐dos* or *medium‐dos* or *standard‐dos* or *middle‐dos* or *maximum‐dos* or *minimum‐dos* or *threshold‐dos*) AND (*haloperi* or *R‐1625* or *haldol* or *alased* or *aloperidi* or *bioperido* or *buterid* or *ceree* or *dozic* or *duraperido* or *fortuna* or *serena* or *serenel* or *seviu* or *sigaperid* or *sylad* or *zafri*) in title abstract and index terms of reference) OR (*haloperidol* and dosage*) in intervention of STUDY] </p> <p>Previous search strategies are shown in <a href="./appendices#CD001951-sec-0186">Appendix 1</a>. </p> </section> </section> <section id="CD001951-sec-0048"> <h4 class="title">Searching other resources</h4> <section id="CD001951-sec-0049"> <h5 class="title">1. Cited reference searching</h5> <p>We inspected the references of all identified trials for more studies. Each of the included studies was sought as a citation on the SCISEARCH database. We inspected reports of articles that had cited these studies in order to identify further trials. </p> </section> <section id="CD001951-sec-0050"> <h5 class="title">2. Search of other Cochrane reviews</h5> <p>We reviewed the included studies of other Cochrane reviews involving haloperidol for potential inclusion. </p> </section> <section id="CD001951-sec-0051"> <h5 class="title">3. Personal contact</h5> <p>We contacted the primary authors of all studies initially selected for inclusion, as well as the authors of Cochrane haloperidol reviews, in order to identify further relevant trials. We also contacted companies producing relevant compounds for copies of published, unpublished, and archived trials. </p> </section> </section> </section> <section id="CD001951-sec-0052"> <h3 class="title" id="CD001951-sec-0052">Data collection and analysis</h3> <p>For details of previous data collection and analysis methods see <a href="./appendices#CD001951-sec-0187">Appendix 2</a>. </p> <section id="CD001951-sec-0053"> <h4 class="title">Selection of studies</h4> <p>For this update, one review author (LD) inspected all abstracts. LD used a random number generator program to select a sample of 10% of all abstracts. CEA then re‐inspected this sample in order to allow selection to be reliable. We resolved any disagreement by discussion, or where there was still doubt, we acquired the full‐text article for further inspection. We obtained full‐text articles of relevant reports and two review authors (LD and CEA) independently decided whether they met the review criteria. We resolved any disagreement by discussion, and, when this was not possible, we sought further information from the study authors. We excluded studies that appeared to meet all inclusion criteria but had no extractable outcomes pending further information from the study authors. </p> </section> <section id="CD001951-sec-0054"> <h4 class="title">Data extraction and management</h4> <section id="CD001951-sec-0055"> <h5 class="title">1. Extraction</h5> <p>LD extracted data from all included studies. CEA independently extracted data from a sample to ensure reliability. Again, we resolved any disagreements by discussion. We extracted data presented in graphs and figures whenever possible, as well as that reported clearly in text. </p> </section> <section id="CD001951-sec-0056"> <h5 class="title">2. Management</h5> <section id="CD001951-sec-0057"> <h6 class="title">2.1 Forms</h6> <p>We extracted data onto standard forms.</p> </section> <section id="CD001951-sec-0058"> <h6 class="title">2.2 Scale‐derived data</h6> <p>A wide range of instruments is available to measure mental health outcomes. These instruments vary in quality and many are not valid, and are known to be subject to bias in trials of treatments for schizophrenia (<a href="./references#CD001951-bbs2-0101" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>). Therefore, we included continuous data from rating scales only if the measuring instrument had been described in a peer‐reviewed journal. </p> </section> <section id="CD001951-sec-0059"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>Where both final endpoint data and change data were available for the same outcome category, we presented only final endpoint data. We acknowledge that by doing this, much of the published change data may be excluded, but argue that endpoint data are more clinically relevant and that if change data were to be presented along with endpoint data, it would be given undeserved equal prominence. We have contacted authors of studies reporting only change data and requested endpoint figures. </p> </section> <section id="CD001951-sec-0060"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on outcomes in mental health trials are often not normally distributed. To avoid applying parametric tests to non‐parametric data, we applied the following standards to all endpoint data derived from continuous measures. The criteria were used before inclusion: (a) standard deviations (SD) and means had to be obtainable; and, for finite scores, such as endpoint measures on rating scales, (b) the SD, when multiplied by two had to be less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution) (<a href="./references#CD001951-bbs2-0043" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313:1200. ">Altman 1996</a>). If a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), which can have values from 30 to 210), the calculation described above in (b) should be modified to take the scale starting point into account. In these cases, skew is present if 2 SD &gt; (S ‐ Smin), where S is the mean score and Smin is the minimum score. </p> <p>Skewed endpoint data from studies with fewer than 200 participants were not shown graphically, but were added to 'Other data' tables and briefly commented on in the text. However, skewed endpoint data from larger studies (≥ 200 participants) pose less of a problem and we entered the data for analysis. </p> <p>For continuous mean change data (endpoint minus baseline), the situation is even more problematic. In the absence of individual patient data, it is impossible to know if change data are skewed. The Review Manager 5 meta‐analyses of continuous data are based on the assumption that the data are, at least to a reasonable degree, normally distributed (<a href="./references#CD001951-bbs2-0121" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>). Therefore, we included such data, unless endpoint data from the same scale were also reported. </p> </section> <section id="CD001951-sec-0061"> <h6 class="title">2.5 Conversion of continuous to binary</h6> <p>Where possible, we attempted to convert outcome measures into binary data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS) (<a href="./references#CD001951-bbs2-0105" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the PANSS (<a href="./references#CD001951-bbs2-0091" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered a clinically significant response (<a href="./references#CD001951-bbs2-0096" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry2005;187:366‐71. ">Leucht 2005a</a>; <a href="./references#CD001951-bbs2-0097" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . What does the PANSS mean?. Schizophrenia Research2005;79:231‐8. ">Leucht 2005b</a>). For many people, especially those with chronic or severe illness, a less rigorous definition of important improvement (e.g. 25% on the BPRS) would be equally valid. If individual patient data were available, we used the 50% cut‐off point for non‐chronically ill people and a 25% cut‐off point for those with chronic illness. If data based on these thresholds were not available, we used the primary cut‐off presented by the original study authors. </p> </section> <section id="CD001951-sec-0062"> <h6 class="title">2.6 Management of dose‐response studies other than fixed‐dose studies</h6> <p>We gave careful consideration to determining a methodology on how to combine studies that used alternate methods of dose allocation, for example plasma studies, neuroleptic threshold studies. We converted the thresholds for dosage groups into plasma thresholds using data from PET research (<a href="./references#CD001951-bbs2-0087" title="KapurS , RemingtonG , JonesC , WilsonA , DaSilvaJ , HouleS , et al. High levels of dopamine D2 receptor occupancy with low‐dose haloperidol treatment: a PET study. American Journal of Psychiatry1996;153(7):948‐50. ">Kapur 1996</a>). These indicated that a 2.1 mg oral dose was approximately equivalent to a 1 ng/mL plasma level. The thresholds for plasma dose ranges in nanograms per millilitre are outlined in <a href="#CD001951-sec-0026">Types of interventions</a>. This approach was affirmed using data from another study (<a href="./references#CD001951-bbs2-0018" title="ChouJC , DouyonR , CzoborP , VolavkaJ , CooperTB . Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research1998;81(1):51‐5. CzoborP , VolavkaJ . Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry1996;37(3):205‐15. CzoborP , VolavkaJ . Positive and negative symptoms: is their change related?. Schizophrenia Bulletin1996;22(4):577‐90. VolavkaJ , CooperTB , CzoborP , MeisnerM . Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. Psychopharmacology Bulletin1996;32(1):75‐9. VolavkaJ , CooperTB , CzoborP , MeisnerM . Haloperidol plasma levels and clinical effects. Psychopharmacology Bulletin1995;31:536. VolavkaJ , CooperTB , CzoborP , MeisnerM . Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry1995;52(10):837‐45. ">Volavka 1995</a>), which reported both oral dose and plasma levels, and there was 100% correspondence between oral dose range allocation and plasma dose allocation using this method. </p> <p>We classified treatment arms from neuroleptic threshold and other flexible‐dose range studies in the same dose ranges as fixed‐dose studies. The criteria used were the following: if the mean dose plus or minus the 50% confidence interval (CI) fell within the predefined fixed‐dose range, or if at least 50% of people in a dose arm had received doses within the prespecified ranges, the flexible treatment arm was considered equivalent to the corresponding fixed‐dose treatment arm. If the dose range from a treatment arm met none of the criteria, then data related to that arm of the study were not extracted. </p> </section> <section id="CD001951-sec-0063"> <h6 class="title">2.7 Management of co‐interventions</h6> <p>We excluded studies that involved randomisation to combined treatments of neuroleptic with additional known psychoactive treatments. We did not exclude studies that allowed for use of other forms of intervention on an 'as needed' basis, or as part of routine clinical practice. </p> </section> <section id="CD001951-sec-0064"> <h6 class="title">2.8 Management of multiple time periods</h6> <p>If data on more than one time point within prespecified time periods were available, we used the duration closest to the middle of the time period. For the greater than six‐month period, we used the longest available time period. </p> </section> <section id="CD001951-sec-0065"> <h6 class="title">2.9. Management of multiple doses</h6> <p>If data were available for more than one dose within the prespecified dosage ranges, we pooled the data from these two doses. </p> </section> <section id="CD001951-sec-0066"> <h6 class="title">2.10 Clinically significant outcomes</h6> <p>Several outcomes were prefixed by the term 'clinically significant'. Wherever possible, we utilised the definition of the authors of the study to define this concept. Where the authors were not specific, we determined that any circumstance that would have led to a significant change in clinical management (e.g. intolerable adverse effects, use of adjunctive medication) was considered clinically significant. For continuous outcomes, we considered a 40% change to be clinically significant. </p> </section> <section id="CD001951-sec-0067"> <h6 class="title">2.11 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD001951-bbs2-0111" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2011:359‐83. ">Schünemann 2011</a>), and used GRADE profiler (<a href="http://www.ims.cochrane.org/revman/gradepro" target="_blank">GRADEPRO</a>), to import data from Review Manager 5 (<a href="./references#CD001951-bbs2-0121" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011. ">RevMan 2011</a>) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to patient care and decision making. We considered treatment with a standard lower dose (&gt; 3 to 7.5 mg/day) versus other doses and selected the following main outcomes for inclusion in the 'Summary of findings' table: </p> <p>1. Leaving the study early;<br/> 2. Clinical response;<br/> 2.1 No clinically significant response in global state;<br/> 3. Extrapyramidal adverse effects;<br/> 3.1 No clinically significant extrapyramidal adverse effects;<br/> 4. Behaviour;<br/> 4.1 Clinically significant agitation. </p> </section> </section> </section> <section id="CD001951-sec-0068"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed risk of bias using the tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001951-bbs2-0076" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). This tool encourages consideration of how the sequence was generated, how allocation was concealed, the integrity of blinding at outcome, the completeness of outcome data, selective reporting and other biases. </p> <p>If disputes arose as to which category a trial had to be allocated, we resolved them by discussion, after working with a third review author. </p> <p>Earlier versions of this review used a different, less well‐developed, means of categorising risk of bias (<a href="./references#CD001951-bbs2-0122" title="WaraichPS , AdamsCE , RoqueM , HamillKM , MartiJ . Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD001951; PUBMED: 12137638] ">Waraich 2002</a>; see <a href="./appendices#CD001951-sec-0188">Appendix 3</a>). </p> </section> <section id="CD001951-sec-0069"> <h4 class="title">Measures of treatment effect</h4> <section id="CD001951-sec-0070"> <h5 class="title">1 Binary data</h5> <p>For binary outcomes, we calculated the risk ratio (RR) and its 95% CI based on the fixed‐effect model. RR is more intuitive than odds ratios (OR) (<a href="./references#CD001951-bbs2-0053" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie1999;54(4):405‐11. ">Boissel 1999</a>), and ORs tend to be interpreted as RRs by clinicians (<a href="./references#CD001951-bbs2-0061" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town, South Africa. 2000. ">Deeks 2000</a>). This misinterpretation then leads to an overestimate of the impression of the effect. The number needed to treat for an additional beneficial outcome (NNTB) and number needed to treat for an additional harmful outcome (NNTH) with its CIs is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD001951-bbs2-0080" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' tables, where possible, we calculated illustrative comparative risks. </p> </section> <section id="CD001951-sec-0071"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes, estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of considerable similarity are used, we presumed there was a small difference in measurement, and we calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD001951-sec-0072"> <h4 class="title">Unit of analysis issues</h4> <section id="CD001951-sec-0073"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ cluster randomisation (such as randomisation by clinician or practice), but analysis and pooling of clustered data poses problems. First, authors often do not account for intraclass correlation (ICC) in clustered studies, leading to a unit‐of‐analysis error (<a href="./references#CD001951-bbs2-0062" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, CIs unduly narrow and statistical significance overestimated. This causes Type I errors (<a href="./references#CD001951-bbs2-0052" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD001951-bbs2-0072" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). </p> <p>Where clustering had not been accounted for in primary studies, we presented the data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review, we will contact first authors of studies to obtain ICCs of their clustered data and to adjust for this using standard methods (<a href="./references#CD001951-bbs2-0072" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149:876‐83. ">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we will also present these data as if from a non‐cluster randomised study, but adjusted for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a design effect. This is calculated using the mean number of participants per cluster (m) and the ICC [Design effect = 1 + (m ‐ 1) *ICC] (<a href="./references#CD001951-bbs2-0063" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomised trials. Statistics in Medicine2002;21:2971‐80. ">Donner 2002</a>). If the ICC was not reported, we assumed it to be 0.1 (<a href="./references#CD001951-bbs2-0116" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). If cluster studies had been appropriately analysed taking into account ICCs and relevant data documented in the report, we combined these with other studies using the generic inverse variance technique. </p> </section> <section id="CD001951-sec-0074"> <h5 class="title">2. Cross‐over design</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a washout phase. For the same reason, cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD001951-bbs2-0066" title="ElbourneDR , AltmanDG , HigginsJP , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: sulpiride versus placebo for schizophrenia 18/22 methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are likely in schizophrenia, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD001951-sec-0075"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involved more than two treatment arms, if relevant, the additional treatment arms were presented in comparisons. Where the additional treatment arms were not relevant, we did not reproduce these data. </p> </section> </section> <section id="CD001951-sec-0076"> <h4 class="title">Dealing with missing data</h4> <section id="CD001951-sec-0077"> <h5 class="title">1. Leaving the study early</h5> <p>We excluded data from studies where more than 50% of participants in any group were lost to follow‐up (this did not include the outcome of 'leaving the study early'), as such data were considered to be too prone to bias. In studies with less than 50% dropout rate, people leaving early were considered to have had a negative outcome, except for the event of death, and dropouts that were clearly attributable to clinical improvement. We analysed the impact of including studies with high attrition rates (25% to 50%) in a sensitivity analysis. If inclusion of data from this latter group resulted in a substantive change in the estimate of effect, we did not add their data to trials with less attrition, but presented them separately. </p> </section> <section id="CD001951-sec-0078"> <h5 class="title">2. Management of deaths</h5> <p>When analysing loss of contacts in studies where deaths had occurred, the 'type' of death affected analysis. Deaths as a result of 'natural causes' were not counted as losses of contact and the number of deaths reduced the size of treatment or control groups. However, we counted suicides or suspicious deaths as loss to follow‐up and their data were incorporated into the analysis. </p> </section> </section> <section id="CD001951-sec-0079"> <h4 class="title">Assessment of heterogeneity</h4> <p>First, we considered all the included studies within any comparison to judge for clinical heterogeneity. Then we visually inspected graphs to investigate the possibility of statistical heterogeneity. We supplemented this by using primarily the I<sup>2</sup> statistic. This provides an estimate of the percentage of variability due to heterogeneity rather than chance alone. Where the I<sup>2</sup> estimate was greater than or equal to 50%, we interpreted this as indicating the presence of considerable levels of heterogeneity (<a href="./references#CD001951-bbs2-0075" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). If inconsistency remained high, and substantially altered the results, we did not add those studies responsible for heterogeneity to the main body of homogeneous trials. We summated the heterogeneous studies and presented them separately and reasons for heterogeneity investigated. </p> </section> <section id="CD001951-sec-0080"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in Section 10.1 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001951-bbs2-0076" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects (<a href="./references#CD001951-bbs2-0065" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). We did not use funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In other cases, where funnel plots were possible, we sought statistical advice in their interpretation. </p> </section> <section id="CD001951-sec-0081"> <h4 class="title">Data synthesis</h4> <p>Where possible we used a fixed‐effect model for analyses. We understand that there is no closed argument for preference for use of fixed‐effect or random‐effects models. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. However, this seems true to us, as random effects put added weight onto the smaller studies ‐ those trials that are most vulnerable to bias. </p> </section> <section id="CD001951-sec-0082"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>When we found heterogeneous results, we investigated the reasons for this. Where heterogeneous data substantially altered the results and the reasons for the heterogeneity were identified, we did not summate these studies in the meta‐analysis, but presented them separately and discussed them in the text. </p> </section> <section id="CD001951-sec-0083"> <h4 class="title">Sensitivity analysis</h4> <p>LD and CEA selected trials that involved people whose illnesses were diagnosed using operational criteria. We also selected trials that involved people whose illnesses were defined as first episode or treatment resistant at the data extraction stage of the review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001951-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001951-sec-0084"></div> <section id="CD001951-sec-0085"> <h3 class="title">Description of studies</h3> <p>For substantive descriptions of studies see: <a href="./references#CD001951-sec-0203" title="">Characteristics of included studies</a>; <a href="./references#CD001951-sec-0204" title="">Characteristics of excluded studies</a>. </p> <section id="CD001951-sec-0086"> <h4 class="title">Results of the search</h4> <p>In this update, we identified 1494 citations in the search, and excluded 1421 because they were not controlled, not randomised or quasi‐randomised, did not primarily involve people with schizophrenia, did not include acutely ill people, were not studies of antipsychotics, involved only one dose of medication, were comparing two doses of an antipsychotic drug but not haloperidol or were duplicate reports of the same trial. Thus, 73 studies remained for the final stage of inclusion/exclusion (<a href="#CD001951-fig-0001">Figure 1</a>). CEA independently assessed a 10% random sample of the original 1494 citations for inclusion/exclusion. LD and CEA agreed on inclusion/exclusion for this 10% sample. </p> <div class="figure" id="CD001951-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (from results of 2010 search only)." data-id="CD001951-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (from results of 2010 search only).</p> </div> </div> </div> <p>Details of citations identified and subsequent processing in the original <a href="./references#CD001951-bbs2-0122" title="WaraichPS , AdamsCE , RoqueM , HamillKM , MartiJ . Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD001951; PUBMED: 12137638] ">Waraich 2002</a> review are shown in <a href="#CD001951-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD001951-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram (2002 review)." data-id="CD001951-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (2002 review).</p> </div> </div> </div> </section> <section id="CD001951-sec-0087"> <h4 class="title">Included studies</h4> <p>See <a href="./appendices#CD001951-sec-0189">Appendix 4</a> for results of the original 2002 review. </p> <p>We included three further studies following this update (<a href="./references#CD001951-bbs2-0001" title="CurtisCE , MannM , PiscaniK , BurrG , HitzemannRJ , HirschowitzJ . A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami. 1995. ">Curtis 1995</a>; <a href="./references#CD001951-bbs2-0005" title="KhannaA , LalN , DalalPK , KhalidA , TrivediJK . Treatment of acute and transient psychotic disorders with low and high doses of oral haloperidol. Indian Journal of Psychiatry1997;39(2):136‐42. ">Khanna 1997</a>; <a href="./references#CD001951-bbs2-0012" title="OosthuizenP , EmsleyR , TurnerHJ , KeyterN . A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first‐episode psychosis. International Journal of Neuropsychopharmacology2004;7(2):125‐31. [MEDLINE: 15003147] ">Oosthuizen 2004</a>), giving 19 studies in the review. The included studies dated between 1967 and 2004. </p> <section id="CD001951-sec-0088"> <h5 class="title">1. Length of studies</h5> <p>The longest study was 10 weeks (<a href="./references#CD001951-bbs2-0007" title="LiangS . Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol. Chinese Journal of Neurology and Psychiatry1987;20(1):43‐8. ">Liang 1987</a>), the shortest was six days (<a href="./references#CD001951-bbs2-0011" title="NeborskyR , DepryD , JanowskyDS , MunsonE , PerelJ . Haloperidol plasma red blood‐cell ratios and clinical efficacy. Psychopharmacology Bulletin1982;18(4):17‐20. NeborskyR , JanowskyD , MunsonE , DepryD . Rapid treatment of acute psychotic symptoms with high‐and low‐dose haloperidol. Behavioral considerations. Archives of General Psychiatry1981;38(2):195‐9. NeborskyR , JanowskyD , MunsonE , HornbeckC , DepryD . Behavioral prediction of response to haloperidol: a test dose strategy. Journal of Clinical Psychiatry1982;43(4):157‐8. NeborskyRJ , JanowskyDS , PerelJM . Red‐blood‐cell plasma haloperidol ratios and antipsychotic efficacy. Psychiatry Research1982;6(1):123‐4. NeborskyRJ , JanowskyDS , PerelJM , MunsonE , DepryD . Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry1984;45(1):10‐3. ">Neborsky 1981</a>). Most studies were between three and six weeks. </p> </section> <section id="CD001951-sec-0089"> <h5 class="title">2. Participants</h5> <p>The largest study involved 132 people (<a href="./references#CD001951-bbs2-0017" title="BitterI , VolavkaJ , CooperJ , Scheurer , CamusL , BakallR . Haloperidol blood levels and clinical effects in schizophrenia. Proceedings of the 8th World Congress of Psychiatry; 1989 Oct 13‐19; Athens, Greece. 1989. ChouJC , DouyonR , CzoborP , VolavkaJ , CooperTB . Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research1998;81(1):51‐5. ConvitA , VolavkaJ , CzoborP , DeAsisJ , EvangelistaC . Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. American Journal of Psychiatry1994;151(1):49‐56. CooperTB , VolavkaJ , CzoborP . Plasma drug level and clinical response. Journal of Clinical Psychopharmacology1992;12(2):134‐6. CzoborP , VolavkaJ . Dimensions of the brief psychiatric rating scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry1996;37(3):205‐15. CzoborP , VolavkaJ . Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Research1992;42(2):129‐44. CzoborP , VolavkaJ . Positive and negative symptoms: is their change related?. Schizophrenia Bulletin1996;22(4):577‐90. CzoborP , VolavkaJ . Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. Journal of Clinical Psychopharmacology1993;13(5):332‐42. KrakowskiM , CzoborP , VolavkaJ . Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Research1997;71(1):19‐26. VolavkaJ , CooperT , CzoborP , BitterI , MeisnerM , LaskaE , et al. Haloperidol blood levels and clinical effects. Archives of General Psychiatry1992;5:354‐61. VolavkaJ , CooperTB , MeisnerM , BitterI , CzoborP , JaegerJ . Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report. Psychopharmacology Bulletin1990;26(1):13‐7. VolavkaJ , DouyonR , ConvitA , CzoborP , CooperTB . Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited. Archives of General Psychiatry1992;49(12):999‐1000. [MEDLINE: 1449388] ">Volavka 1992</a>), the smallest (<a href="./references#CD001951-bbs2-0015" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9(8):401‐12. ">Simpson 1967</a>) only 16 people. Only three of the included trials did not report stringent criteria for the diagnosis of schizophrenia (<a href="./references#CD001951-bbs2-0001" title="CurtisCE , MannM , PiscaniK , BurrG , HitzemannRJ , HirschowitzJ . A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami. 1995. ">Curtis 1995</a>; <a href="./references#CD001951-bbs2-0002" title="DonlonPT , HopkinJT , TupinJP , WicksJJ , WahbaM , MeadowA . Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Archives of General Psychiatry1980;6:691‐5. WahbaM , DonlonPT , MeadowA . Cognitive changes in acute schizophrenia with brief neuroleptic treatment. American Journal of Psychiatry1981;138(10):1307‐10. ">Donlon 1980</a>; <a href="./references#CD001951-bbs2-0015" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9(8):401‐12. ">Simpson 1967</a>). In the other studies, diagnoses were established by structured interviews or clinical examination by a psychiatrist and the diagnostic criteria applied included Research Diagnostic Criteria (RDC), ICD and DSM. </p> <p>Although sometimes demographic data were missing, participants tended to be acutely ill men or women in their 20s or 30s. People had often been recently admitted to hospital, although some studies included acutely ill people who had been in hospital for months or years. Most studies involved people who had been ill before and for some time. One study used subjects with a first episode of psychosis (<a href="./references#CD001951-bbs2-0012" title="OosthuizenP , EmsleyR , TurnerHJ , KeyterN . A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first‐episode psychosis. International Journal of Neuropsychopharmacology2004;7(2):125‐31. [MEDLINE: 15003147] ">Oosthuizen 2004</a>). </p> </section> <section id="CD001951-sec-0090"> <h5 class="title">3. Interventions</h5> <p>Doses of haloperidol varied from a low of 1 mg/day (<a href="./references#CD001951-bbs2-0004" title="KapurS , ZipurskyR , JonesC , RemingtonG , HouleS . Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double‐blind PET study of first‐episode schizophrenia. American Journal of Psychiatry2000;4:514‐20. ">Kapur 2000</a>) to a high of up to 100 mg/day (<a href="./references#CD001951-bbs2-0002" title="DonlonPT , HopkinJT , TupinJP , WicksJJ , WahbaM , MeadowA . Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Archives of General Psychiatry1980;6:691‐5. WahbaM , DonlonPT , MeadowA . Cognitive changes in acute schizophrenia with brief neuroleptic treatment. American Journal of Psychiatry1981;138(10):1307‐10. ">Donlon 1980</a>). Doses were commonly fixed, perhaps preceded by a titration up to the final dose, and were given orally. The most common comparison (5/13) was standard higher dose (&gt; 7.5 to 15 mg/day) versus high dose (&gt; 15 to 35 mg/day). </p> <p>One study had grouped participants in such a way that the control group straddled both our standard higher and high intervention group (<a href="./references#CD001951-bbs2-0008" title="Louza NetoMR , Muller SpahnF , RutherE , SchererJ . Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry1988;21(5):226‐31. [MEDLINE: 3227054] ">Louza 1988</a>). Four out of 19 randomised trials focused on plasma levels rather than dose. </p> </section> <section id="CD001951-sec-0091"> <h5 class="title">4. Outcomes</h5> <p>All included studies, with the exception of <a href="./references#CD001951-bbs2-0001" title="CurtisCE , MannM , PiscaniK , BurrG , HitzemannRJ , HirschowitzJ . A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami. 1995. ">Curtis 1995</a>, reported 'leaving the study early' and most reported usable data on global state. Definitions of 'no clinically significant improvement' differed across studies. It was difficult to decide whether the results concerning clinical improvement were comparable. It seemed unlikely, however, that those judging improvement would have applied such dramatically differing criteria as to make summation inappropriate, especially given that analysis was restricted to randomised comparisons only. Further, if convergence of effects occurs despite differing methods, this may enhance the applicability of findings. </p> <p>Mental state was reported in a form that was useful for this review in 11 of the included studies, and some adverse effects were clearly reported in 12 studies. All scale‐derived data that we were able to present were from two studies (<a href="./references#CD001951-bbs2-0012" title="OosthuizenP , EmsleyR , TurnerHJ , KeyterN . A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first‐episode psychosis. International Journal of Neuropsychopharmacology2004;7(2):125‐31. [MEDLINE: 15003147] ">Oosthuizen 2004</a>; <a href="./references#CD001951-bbs2-0014" title="DoddiS , RifkinA , KarajgiB , CooperT , BorensteinM . Blood levels of haloperidol and clinical outcome in schizophrenia. Journal of Clinical Psychopharmacology1994;14(3):187‐95. RifkinA , DoddiS , KarajgiB , BorensteinM , WachspressM . Dosage of haloperidol for schizophrenia. Archives of General Psychiatry1991;48(2):166‐70. ">Rifkin 1991</a>). </p> <p>We describe scales used by included studies to collect data.</p> <section id="CD001951-sec-0092"> <h6 class="title">4.1 Clinical Global Impression</h6> <p>Clinical Global Impression (CGI) is a rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify severity of illness and overall clinical improvement during therapy. Generally, a seven‐point scoring system is used, with low scores indicating decreased severity or greater recovery, or both (<a href="./references#CD001951-bbs2-0073" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976. ">Guy 1976</a>). </p> </section> <section id="CD001951-sec-0093"> <h6 class="title">4.2 Schedule for Affective Disorders and Schizophrenia</h6> <p>Schedule for Affective Disorders and Schizophrenia (SADS) makes use of collateral information and past history. It rates symptoms at their highest level of severity over the previous week. Used serially, it provides a detailed record of the individual's progress. Greater scores indicate more severe symptoms (<a href="./references#CD001951-bbs2-0068" title="EndicottJ , SpitzerRL . A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry1978;35:837‐44. ">Endicott 1978</a>). </p> </section> <section id="CD001951-sec-0094"> <h6 class="title">4.3 Simpson and Angus Scale</h6> <p>Simpson and Angus Scale is a standard physical examination that measures parkinsonism. This scale is comprised of a 10‐item rating scale, each item rated on a five‐point scale with zero indicating the complete absence of condition and four indicating the presence of condition in extreme. Adding the items and dividing by 10 obtains the total score (<a href="./references#CD001951-bbs2-0112" title="SimpsonM , AngusJW . A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;212:11‐9. ">Simpson 1970</a>). </p> </section> <section id="CD001951-sec-0095"> <h6 class="title">4.4 Calgary Depression Rating Scale</h6> <p>The Calgary Depression Rating Scale is the standard rating scale for measuring depression in people with schizophrenia. This is a semi‐structured interview that scores nine items on a scale of absent, mild, moderate and severe (<a href="./references#CD001951-bbs2-0042" title="AddingtonD , AddingtonJ , SchisselB . A depression rating scale for schizophrenics. Schizophrenia Research1990;3:247‐51. ">Addington 1990</a>). </p> </section> <section id="CD001951-sec-0096"> <h6 class="title">4.5 Positive and Negative Symptoms of Schizophrenia</h6> <p>PANSS is a relatively brief structured interview commonly used in the study of antipsychotic therapy. It rates positive and negative symptoms as defined by the American Psychiatric Association scoring one to seven on 30 different items. It constitutes four scales measuring positive and negative symptoms, their differential and general severity of illness (<a href="./references#CD001951-bbs2-0091" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>). </p> </section> </section> </section> <section id="CD001951-sec-0097"> <h4 class="title">Excluded studies</h4> <p>We added a further six studies to the excluded studies section of the review following this update giving 22 studies. Several reported outcomes in such a way that made inclusion impossible. Either data did not have clear clinical implications, for example EEG recordings, or relevant clinical data were inadequately reported. Frequently, the numbers of participants in each group were not specified, means or SDs were not reported, or data were not reported from individual arms of cross‐over studies. </p> <section id="CD001951-sec-0098"> <h5 class="title">Awaiting assessment</h5> <p>There are no studies currently awaiting assessment.</p> </section> <section id="CD001951-sec-0099"> <h5 class="title">Ongoing</h5> <p>The review authors know of no ongoing studies.</p> </section> </section> </section> <section id="CD001951-sec-0100"> <h3 class="title">Risk of bias in included studies</h3> <p>We used the tool for assessment of bias described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001951-bbs2-0076" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), and a graphical overview can be seen in <a href="#CD001951-fig-0003">Figure 3</a> and <a href="#CD001951-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD001951-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001951-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD001951-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001951-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD001951-sec-0101"> <h4 class="title">Allocation</h4> <p>The quality of randomisation in the studies was generally unclear. All studies were described as 'randomised'. Only one study described using random number tables to achieve randomisation (<a href="./references#CD001951-bbs2-0007" title="LiangS . Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol. Chinese Journal of Neurology and Psychiatry1987;20(1):43‐8. ">Liang 1987</a>). Most studies simply reported randomisation and presented baseline data that were equivalent for the different comparator groups. </p> </section> <section id="CD001951-sec-0102"> <h4 class="title">Blinding</h4> <p>All studies were reported as 'double‐blind' with the exception of <a href="./references#CD001951-bbs2-0001" title="CurtisCE , MannM , PiscaniK , BurrG , HitzemannRJ , HirschowitzJ . A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami. 1995. ">Curtis 1995</a>. Several trials described using identical methods of dose delivery between groups. Only <a href="./references#CD001951-bbs2-0015" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9(8):401‐12. ">Simpson 1967</a> tested this by asking ward staff to guess the allocated treatment (91% of doctors and 89.5% of nurses were able to guess correctly). </p> </section> <section id="CD001951-sec-0103"> <h4 class="title">Incomplete outcome data</h4> <p>The majority of studies described the numbers of people leaving early and reasons for leaving. Of the 19 studies, six described intention‐to‐treat analysis, nine described a 'per protocol' analysis and four did not report if dropout data were included in the analyses. </p> </section> <section id="CD001951-sec-0104"> <h4 class="title">Selective reporting</h4> <p>The majority of the studies report a wide range of both statistically significant and non‐significant outcomes but few reported all outcome measures. One paper presented only highly significant results (<a href="./references#CD001951-bbs2-0009" title="McEvoyJP , HogartyGE , SteingardS . Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold. Archives of General Psychiatry1991;48(8):739‐45. McEvoyJP , SchoolerNR , WilsonWH . Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin1991;27(2):97‐101. ">McEvoy 1991</a>), and another did not report results from one treatment group (<a href="./references#CD001951-bbs2-0001" title="CurtisCE , MannM , PiscaniK , BurrG , HitzemannRJ , HirschowitzJ . A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami. 1995. ">Curtis 1995</a>). </p> </section> <section id="CD001951-sec-0105"> <h4 class="title">Other potential sources of bias</h4> <p>We noted no obvious other sources of bias for this update.</p> </section> </section> <section id="CD001951-sec-0106"> <h3 class="title" id="CD001951-sec-0106">Effects of interventions</h3> <p>See: <a href="./full#CD001951-tbl-0001"><b>Summary of findings for the main comparison</b> STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</a> </p> <p>All the studies included in the review so far had outcomes assessed before 10 weeks, so no data could be presented for longer periods (greater than 10 weeks to six months, greater than six months). For several of the comparisons, the same data from a specific study were re‐presented several times. For example, one study may have compared low‐dose and high‐dose haloperidol. Therefore, we considered it was appropriate to present these data in both comparison number 2, where low dose is the 'experimental intervention' and high the 'control' and comparison number 6, where the opposite applies. </p> <p>We are aware that presenting the findings in this way does, at times, result in the repeating of results ‐ but in reverse, for example the low dose versus high dose is listed twice as it appears later as high dose versus low dose. This makes results long and repetitive ‐ although because we are using the RR rather than OR the figures do change. It is feasible to restructure the review but to not repeat listings would have asked more of the reader. For this version we have left the structure of the review as it was originally (<a href="./references#CD001951-bbs2-0122" title="WaraichPS , AdamsCE , RoqueM , HamillKM , MartiJ . Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD001951; PUBMED: 12137638] ">Waraich 2002</a>), with each comparison containing all available data for that particular question (see <a href="#CD001951-sec-0179">Implications for research</a>). </p> <section id="CD001951-sec-0107"> <h4 class="title">1. DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES</h4> <p>We found one small (n = 26) study comparing ultra low dose with low dose (&gt; 1.5 to 3 mg/day) (<a href="./references#CD001951-bbs2-0004" title="KapurS , ZipurskyR , JonesC , RemingtonG , HouleS . Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double‐blind PET study of first‐episode schizophrenia. American Journal of Psychiatry2000;4:514‐20. ">Kapur 2000</a>). </p> <section id="CD001951-sec-0108"> <h5 class="title">1.1 Leaving the study early</h5> <p>We found no significant difference between study groups in rates of people leaving the study early (n = 26, 1 RCT, RR 0.29, 95% CI 0.03 to 2.4). </p> </section> <section id="CD001951-sec-0109"> <h5 class="title">1.2 Global state</h5> <p>We found no significant difference between study groups (n = 26, 1 RCT, RR 1.89, 95% CI 0.9 to 3.9) though numerically there were more people who showed no significant response in the ultra low group (11/14 versus 5/12). Again, there was no significant difference between groups in use of adjunctive medication for sedation (<a href="./references#CD001951-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD001951-sec-0110"> <h5 class="title">1.3 Mental state/behaviour</h5> <p>There was no significant difference in frequency of clinically significant agitation between groups (<a href="./references#CD001951-fig-0008" title="">Analysis 1.4</a>). </p> </section> <section id="CD001951-sec-0111"> <h5 class="title">1.4 Adverse effects</h5> <p>We found no significant difference in extrapyramidal side effect (EPSE) rates between groups (n = 26, 1 RCT, RR 0.51, 95% CI 0.15 to 1.7). We also found no significant difference in use of antiparkinsonism drugs between groups (n = 26, 1 RCT, RR 0.5, 95% CI 0.15 to 1.7). </p> </section> </section> <section id="CD001951-sec-0112"> <h4 class="title">2. DOSES: 2. LOW DOSE (&gt; 1.5 to 3 mg/day) versus OTHER DOSES</h4> <p>We found one small study (n = 26) comparing low dose with ultra low dose (&gt; 0.25 to 1.5 mg/day) (<a href="./references#CD001951-bbs2-0004" title="KapurS , ZipurskyR , JonesC , RemingtonG , HouleS . Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double‐blind PET study of first‐episode schizophrenia. American Journal of Psychiatry2000;4:514‐20. ">Kapur 2000</a>). A further small study compared low dose with standard higher dose (&gt; 7.5 to 15 mg/day) (<a href="./references#CD001951-bbs2-0012" title="OosthuizenP , EmsleyR , TurnerHJ , KeyterN . A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first‐episode psychosis. International Journal of Neuropsychopharmacology2004;7(2):125‐31. [MEDLINE: 15003147] ">Oosthuizen 2004</a>). </p> <section id="CD001951-sec-0113"> <h5 class="title">2.1 Leaving the study early</h5> <p>We found few participants left before completion with no clear difference in acceptability between low dose and ultra low dose (n = 26, 1 RCT, RR 3.5, 95% CI 0.4 to 29).<br/> We found there were numerically more dropouts in the standard higher dose (8/20) than the low dose (3/20) groups, but this difference was not statistically significant. </p> </section> <section id="CD001951-sec-0114"> <h5 class="title">2.2 Global state</h5> <p>More people in the ultra low dose group showed no significant response during the study than in the low dose group. This did not reach conventional levels of statistical significance (n = 26, 1 RCT, RR 0.53, 95% CI 0.3 to 1.1). Use of adjunctive medication for sedation occurred less frequently in the ultra low dose group compared with low dose group, but again not to a statistically significant degree (n = 26, 1 RCT, RR 1.75, 95% CI 0.4 to 9). Mean dose of lorazepam was also similar between low and standard higher dose groups (<a href="./references#CD001951-fig-0015" title="">Analysis 2.5</a>), as was endpoint CGI scores (<a href="./references#CD001951-fig-0014" title="">Analysis 2.4</a>). </p> </section> <section id="CD001951-sec-0115"> <h5 class="title">2.3 Mental state/behaviour</h5> <p>Clinically significant agitation was infrequent and no different in either low or ultra low groups (n = 26, 1 RCT, RR 1.75, 95% CI 0.4 to 9). Data comparing low dose with standard higher doses was presented as endpoint PANSS differential scores (<a href="./references#CD001951-fig-0017" title="">Analysis 2.7</a>; <a href="./references#CD001951-fig-0019" title="">Analysis 2.9</a>), CGI scores (<a href="./references#CD001951-fig-0014" title="">Analysis 2.4</a>), and Calgary Depression Rating Scale scores (<a href="./references#CD001951-fig-0020" title="">Analysis 2.10</a>), which were all highly skewed with the exception of the PANSS positive subscale, which showed no significant difference between groups (n = 40, 1 RCT, MD 0.8, 95% CI ‐4.1 to 5.7). </p> </section> <section id="CD001951-sec-0116"> <h5 class="title">2.4 Adverse effects</h5> <p>EPAEs were less frequent for people allocated the ultra low dose compared to low dose, but not to a statistically significant degree (n = 26, 1 RCT, RR 1.94, 95% CI 0.6 to 6.5), as did use of antiparkinsonism drugs (n = 26, 1 RCT, RR 1.94, 95% CI 0.6 to 6.5). </p> <p>Dystonic reactions (n = 40, 1 RCT, RR 0.33, 95% CI 0.1 to 1.5), dyskinesia (n = 40, 1 RCT, RR 0.2, 95% CI 0.01 to 3.9) and akathisia (n = 40, 1 RCT, RR 0.38, 95% CI 0.1 to 1.2) occurred more commonly in the standard higher dose group compared to the low dose group but the differences were not statistically significant. Mean dose of orphenadrine used in the standard higher dose group was significantly higher than in the low dose range, though data were skewed (<a href="./references#CD001951-fig-0023" title="">Analysis 2.13</a>). Similarly, prolactin levels at endpoint were significantly higher in the standard higher dose group though data were again skewed (<a href="./references#CD001951-fig-0027" title="">Analysis 2.17</a>). </p> </section> </section> <section id="CD001951-sec-0117"> <h4 class="title">3. DOSES: 3. STANDARD LOWER DOSE (&gt; 3 mg to 7.5 mg/day) versus OTHER DOSES</h4> <section id="CD001951-sec-0118"> <h5 class="title">3.1 Leaving the study early</h5> <p>Standard lower dose was more acceptable than standard higher dose (&gt; 7.5 to 15 mg/day) (n = 64, 2 RCTs, RR 0.1, 95% CI 0.01 to 2.1). When the standard lower dose was compared with high dose (&gt; 15 to 35 mg/day) the results did not conclusively show that the lower of the two doses was more acceptable. This did not reach a statistically significant level (n = 191, 4 RCTs, RR 0.78, 95% CI 0.5 to 1.3). There also was no discernible difference in the numbers leaving the groups early when the standard lower dose was compared with very high dose (&gt; 35 mg/day) (n = 86, 2 RCTs, RR 0.7, 95% CI 0.3 to 1.6). </p> </section> <section id="CD001951-sec-0119"> <h5 class="title">3.2 Global state</h5> <p>About the same numbers of people allocated to the standard lower dose group showed no clinically important improvement in global state compared with standard higher dose (n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.8) and with high dose (n = 81, 2 RCTs, RR 0.95, 95% CI 0.8 to 1.2). The need for sedative medication was evenly balanced between standard lower and standard higher dose groups (n = 238, 4 RCT, RR 0.99, 95% CI 0.8 to 1.2). </p> </section> <section id="CD001951-sec-0120"> <h5 class="title">3.3 Mental state/behaviour</h5> <p>One small study (n = 65) reported on agitation (<a href="./references#CD001951-bbs2-0018" title="ChouJC , DouyonR , CzoborP , VolavkaJ , CooperTB . Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research1998;81(1):51‐5. CzoborP , VolavkaJ . Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry1996;37(3):205‐15. CzoborP , VolavkaJ . Positive and negative symptoms: is their change related?. Schizophrenia Bulletin1996;22(4):577‐90. VolavkaJ , CooperTB , CzoborP , MeisnerM . Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. Psychopharmacology Bulletin1996;32(1):75‐9. VolavkaJ , CooperTB , CzoborP , MeisnerM . Haloperidol plasma levels and clinical effects. Psychopharmacology Bulletin1995;31:536. VolavkaJ , CooperTB , CzoborP , MeisnerM . Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry1995;52(10):837‐45. ">Volavka 1995</a>). There was no difference for those allocated standard lower dose compared with high dose (RR 0.93, 95% CI 0.7 to 1.3). </p> </section> <section id="CD001951-sec-0121"> <h5 class="title">3.4 Adverse effects</h5> <p>Adverse effects were measured by development of clinically significant EPSE and use of antiparkinsonism drugs. </p> <p>Compared with standard higher dose, the standard lower dose was not shown to spare people clinically significant EPAEs (n = 64, 2 RCTs, RR 0.12, 95% CI 0.01 to 2.1). Compared with a high dose, people allocated the standard lower dose had fewer adverse effects (n = 144, 3 RCTs, RR 0.59, 95% CI 0.5 to 0.8, NNTH 3, 95% CI 2 to 6). When the same standard lower dose was compared with very high dose, however, this finding was not replicated (n = 86, 2 RCTs, RR 0.7, 95% CI 0.5 to 1.1). </p> </section> </section> <section id="CD001951-sec-0122"> <h4 class="title">4. DOSES: 4. STANDARD HIGHER DOSE (7.5 to 15 mg/day) versus OTHER DOSES</h4> <section id="CD001951-sec-0123"> <h5 class="title">4.1 Mortality</h5> <p>Only one small study (n = 20), comparing standard higher dose with very high dose (&gt; 35 mg/day), reported on death stating that none had occurred (<a href="./references#CD001951-bbs2-0011" title="NeborskyR , DepryD , JanowskyDS , MunsonE , PerelJ . Haloperidol plasma red blood‐cell ratios and clinical efficacy. Psychopharmacology Bulletin1982;18(4):17‐20. NeborskyR , JanowskyD , MunsonE , DepryD . Rapid treatment of acute psychotic symptoms with high‐and low‐dose haloperidol. Behavioral considerations. Archives of General Psychiatry1981;38(2):195‐9. NeborskyR , JanowskyD , MunsonE , HornbeckC , DepryD . Behavioral prediction of response to haloperidol: a test dose strategy. Journal of Clinical Psychiatry1982;43(4):157‐8. NeborskyRJ , JanowskyDS , PerelJM . Red‐blood‐cell plasma haloperidol ratios and antipsychotic efficacy. Psychiatry Research1982;6(1):123‐4. NeborskyRJ , JanowskyDS , PerelJM , MunsonE , DepryD . Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry1984;45(1):10‐3. ">Neborsky 1981</a>). </p> </section> <section id="CD001951-sec-0124"> <h5 class="title">4.2 Leaving the study early</h5> <p>Two studies comparing standard higher dose with very high dose reported early study attrition (between 3 and 14 days). There was no clear difference between groups (n = 83, 2 RCTs, RR 0.72, 95% CI 0.3 to 2). One study reported one participant leaving on day one or two (<a href="./references#CD001951-bbs2-0008" title="Louza NetoMR , Muller SpahnF , RutherE , SchererJ . Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry1988;21(5):226‐31. [MEDLINE: 3227054] ">Louza 1988</a>). </p> <p>Several studies reported attrition between two and 10 weeks. There was no difference between the standard higher dose group and low dose (&gt; 1.5 to 3 mg/day) (n = 40, 1 RCT, RR 2.67, 95% CI 0.8 to 8.6), standard lower dose (&gt; 3 to 7.5 mg/day) (n = 64, 2 RCTs, RR 8.31, 95% CI 0.5 to 146), high dose (&gt; 15 to 35 mg/day) (n = 188, 4 RCTs, RR 0.87, 95% CI 0.5 to 1.7), or very high dose (n = 74, 2 RCTs, RR 0.62, 95% CI 0.3 to 1.5). </p> </section> <section id="CD001951-sec-0125"> <h5 class="title">4.3 Global state</h5> <p>One study comparing standard higher dose with very high dose reported early appraisal of global state (between 3 and 14 days). There was no clear difference between groups (n = 20, 1 RCT, RR 3.0, 95% CI 0.4 to 24). </p> <p>A series of small trials, even when combined, showed no difference for the outcome of 'no significant global improvement' when standard higher dose was compared with standard lower dose (n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.7), high dose (n = 106, 2 RCTs, RR 1.33, 95% CI 0.9 to 2.1), or very high dose (n = 58, 1 RCT, RR 1.29, 95% CI 0.8 to 2). </p> <p>Mean change scores were also equivocal. Numbers of people needing additional sedation not significantly when standard higher dose was compared with high dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high dose (n = 58, 1 RCT, RR 1.43, 95% CI 0.6 to 3). </p> <p>One trial reported endpoint CGI scores (<a href="./references#CD001951-fig-0044" title="">Analysis 4.9</a>) and mean use of lorazepam (<a href="./references#CD001951-fig-0045" title="">Analysis 4.10</a>) in standard higher and low dose groups. The results were similar between groups and skewed. </p> </section> <section id="CD001951-sec-0126"> <h5 class="title">4.4 Mental state/behaviour</h5> <p>Early appraisal of psychotic symptoms (between 3 and 14 days) was undertaken in the one study that compared standard higher dose with very high dose. There was no clear difference between groups (n = 20, 1 RCT, RR 3.0, 95% CI 0.4 to 24). </p> <p>PANSS positive subscale endpoint score was not significantly different between standard higher and low dose groups (n = 40, 1 RCT, MD ‐0.8, 95% CI ‐5.56 to 3.96). PANSS general score (<a href="./references#CD001951-fig-0048" title="">Analysis 4.13</a>), PANSS negative subscale (<a href="./references#CD001951-fig-0050" title="">Analysis 4.15</a>) and Calgary Depression Rating Scale (<a href="./references#CD001951-fig-0051" title="">Analysis 4.16</a>) were all similar between groups and skewed. </p> <p><a href="./references#CD001951-bbs2-0014" title="DoddiS , RifkinA , KarajgiB , CooperT , BorensteinM . Blood levels of haloperidol and clinical outcome in schizophrenia. Journal of Clinical Psychopharmacology1994;14(3):187‐95. RifkinA , DoddiS , KarajgiB , BorensteinM , WachspressM . Dosage of haloperidol for schizophrenia. Archives of General Psychiatry1991;48(2):166‐70. ">Rifkin 1991</a> reported on agitation between 2 and 10 weeks, but showed no differences between standard higher dose and high dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high dose (n = 58, 1 RCT, RR 1.43, 95% CI 0.6 to 3). </p> </section> <section id="CD001951-sec-0127"> <h5 class="title">4.5 Adverse effects</h5> <p>Acute dystonia was no more common in those allocated standard higher dose than in people given very high dose (n = 63, 1 RCT, RR 0.69, 95% CI 0.4 to 1.2). Neither were clinically significant EPAEs clearly more common for people taking standard higher dose than those given standard lower dose (n = 64, 2 RCTs, RR 8.3, 95% CI 0.5 to 146). Mean change scores for EPAEs were also equivocal. Conversely, dystonic reaction (n = 40, 1 RCT, RR 3, 95% CI 0.7 to 13.1), dyskinesia (n = 40, 1 RCT, RR 5, 95% CI 0.3 to 98) and akathisia (n = 40, 1 RCT, RR 2.7, 95% CI 0.8 to 8.6) appeared more common in the standard higher dose group than the low dose group though not to a significant level. </p> <p><a href="./references#CD001951-bbs2-0008" title="Louza NetoMR , Muller SpahnF , RutherE , SchererJ . Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry1988;21(5):226‐31. [MEDLINE: 3227054] ">Louza 1988</a> compared EPSE between standard higher dose versus high and very high doses combined but again, there was no significant difference (<a href="./references#CD001951-fig-0056" title="">Analysis 4.21</a>). </p> <p>Mean values of orphenadrine used (<a href="./references#CD001951-fig-0057" title="">Analysis 4.22</a>) and endpoint prolactin levels (<a href="./references#CD001951-fig-0060" title="">Analysis 4.25</a>) were significantly higher in the standard higher dose group to the low dose group, though data were skewed. </p> <p>Finally, only one study reported on postural hypertension (n = 63) but showed no difference between people taking standard higher dose compared with people taking very high dose (RR 0.7, 95% CI 0.03 to 16) (<a href="./references#CD001951-bbs2-0002" title="DonlonPT , HopkinJT , TupinJP , WicksJJ , WahbaM , MeadowA . Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Archives of General Psychiatry1980;6:691‐5. WahbaM , DonlonPT , MeadowA . Cognitive changes in acute schizophrenia with brief neuroleptic treatment. American Journal of Psychiatry1981;138(10):1307‐10. ">Donlon 1980</a>). </p> </section> </section> <section id="CD001951-sec-0128"> <h4 class="title">5. DOSES: 5. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</h4> <section id="CD001951-sec-0129"> <h5 class="title">5.1 Leaving the study early</h5> <p>No differences were apparent when high dose was compared with standard lower dose (&gt; 3 to 7.5 mg/day) (n = 191, 4 RCTs, RR 1.28, 95% CI 0.8 to 2.1), standard higher dose (&gt; 7.5 to 15 mg/day) (n = 188, 4 RCTs, RR 1.16, 95% CI 0.6 to 2.2) and very high dose (&gt; 35 mg/day) (n = 312, 5 RCTs, RR 1.04, 95% CI 0.7 to 1.6). </p> </section> <section id="CD001951-sec-0130"> <h5 class="title">5.2 Global state</h5> <p>Even combination of several studies found no differences when high dose was compared with standard lower dose (n = 81, 2 RCTs, RR 1.06, 95% CI 0.8 to 1.3) and very high dose (n = 255, 4 RCTs, RR 0.92, 95% CI 0.8 to 1.1). Change scores also found no clear differences when high dose was compared with standard higher dose and very high dose . One study used the outcome of 'no psychotic symptoms' to compare high dose and standard lower dose but no people in either group met the description. </p> <p>The risk of needing additional sedation was greater for people given high dose compared with standard lower dose (n = 144, 3 RCTs, RR 1.40, 95% CI 1.1 to 1.8, NNTH 3, 95% CI 2 to 6). No differences were apparent when high dose was compared with standard higher dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), and very high dose (n = 115, 2 RCTs, RR 1.07, 95% CI 0.7 to 1.7). The use of sedatives at high dose compared to standard lower dose between 0 and 14 days specifically was not significant (n = 47, 1 RCT, RR 0.74, 95% CI 0.4 to 1.3), similarly between 2 and 10 weeks (n = 47, 1 RCT, RR 0.29, 95% CI 0.03 to 2.6). </p> </section> <section id="CD001951-sec-0131"> <h5 class="title">5.3 Mental state/behaviour</h5> <p>For the outcome of 'no clinically important change in psychotic symptoms' there were no differences for those given high dose compared with people allocated to very high dose (n = 92, 1 RCT, RR 1.57, 95% CI 0.8 to 3.1). </p> <p>Agitation was equally common for people given high dose versus standard lower dose (n = 65, 1 RCT, RR 1.08, 95% CI 0.8 to 1.5), standard higher dose (n = 58, 1 RCT, RR 1.0, 95% CI 0.5 to 2), or very high doses (n = 115, 2 RCTs, RR 1.07, 95% CI 0.7 to 1.7). Mean scores were also equivocal. Although sustained high doses of haloperidol are extensively used to treat agitation in acute phases of schizophrenia (<a href="./references#CD001951-bbs2-0049" title="BaldessariniRJ , CohenBM , TeicherMH . Significance of neuroleptic dose and plasma level in the pharmacologic treatment of psychoses. Archives of General Psychiatry1988;45:79‐91. ">Baldessarini 1988</a>), there were no statistically significant differences between the dose ranges in studies that reported on this outcome. However, there are few studies that examine this outcome. </p> <p>It should be emphasised that this review does not have any information regarding the benefits and tolerability of 'as needed' doses of antipsychotics. For this, readers should examine the findings from a complementary Cochrane review (<a href="./references#CD001951-bbs2-0117" title="WhicherE , MorrisonM , Douglas‐HallP . 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD003441.pub2] ">Whicher 2002</a>). </p> </section> <section id="CD001951-sec-0132"> <h5 class="title">5.4 Adverse effects</h5> <p>High doses resulted in more EPAEs than standard lower doses (n = 144, 3 RCTs, RR 1.7, 95% CI 1.3 to 2.2, NNTH 3, 95% CI 2 to 6), but the same levels as very high doses (n = 114, 2 RCTs, RR 1.03, 95% CI 0.7 to 1.4). Change scores in ratings of EPAEs were, compared with standard higher dose and very high doses, equivocal and uninformative. More people allocated to high dose needed drugs to counter parkinsonism compared with standard lower dose (n = 144, 3 RCTs, RR 1.7, 95% CI 1.3 to 2.2, NNTH 3, 95% CI 2 to 6). Compared with very high doses people given high dose did not need more antiparkinsonism drugs (n = 114, 2 RCTs, RR 1.13, 95% CI 0.9 to 1.4). Akathisia was as common for people allocated to high dose as people allocated to very high dose (n = 57, 1 RCT, RR 0.71, 95% CI 0.4 to 1.4). </p> <p>One study considered blurred vision in high and standard lower dose groups, but there was no significant difference between the groups. </p> </section> </section> <section id="CD001951-sec-0133"> <h4 class="title">6. DOSES: 6. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</h4> <section id="CD001951-sec-0134"> <h5 class="title">6.1 Mortality</h5> <p>Only one small study (n = 20), comparing standard higher dose (&gt; 7.5 to 15 mg/day) with very high dose, reported on death, stating that none had occurred (<a href="./references#CD001951-bbs2-0011" title="NeborskyR , DepryD , JanowskyDS , MunsonE , PerelJ . Haloperidol plasma red blood‐cell ratios and clinical efficacy. Psychopharmacology Bulletin1982;18(4):17‐20. NeborskyR , JanowskyD , MunsonE , DepryD . Rapid treatment of acute psychotic symptoms with high‐and low‐dose haloperidol. Behavioral considerations. Archives of General Psychiatry1981;38(2):195‐9. NeborskyR , JanowskyD , MunsonE , HornbeckC , DepryD . Behavioral prediction of response to haloperidol: a test dose strategy. Journal of Clinical Psychiatry1982;43(4):157‐8. NeborskyRJ , JanowskyDS , PerelJM . Red‐blood‐cell plasma haloperidol ratios and antipsychotic efficacy. Psychiatry Research1982;6(1):123‐4. NeborskyRJ , JanowskyDS , PerelJM , MunsonE , DepryD . Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry1984;45(1):10‐3. ">Neborsky 1981</a>). </p> </section> <section id="CD001951-sec-0135"> <h5 class="title">6.2 Leaving the study early</h5> <p>Two studies comparing very high dose with standard higher dose reported early study attrition (between 3 and 14 days). There was no clear difference between groups (n = 83, 2 RCTs, RR 1.4, 95% CI 0.5 to 4). </p> <p>Several studies reported study attrition between 2 and 10 weeks. There was no clear difference between the very high dose group and standard lower dose (&gt; 3 to 7.5 mg/day) (n = 86, 2 RCTs, RR 1.42, 95% CI 0.6 to 3.2), standard higher dose (n = 74, 2 RCTs, RR 1.62, 95% CI 0.7 to 4), or high dose (&gt; 15 to 35 mg/day) (n = 312, 5 RCTs, RR 0.96, 95% CI 0.6 to 1.5). </p> </section> <section id="CD001951-sec-0136"> <h5 class="title">6.3 Global state</h5> <p>One study comparing very high dose with standard higher dose reported early appraisal of global state (between 3 and 14 days). There was no clear difference between groups (n = 20, 1 RCT, RR 0.33, 95% CI 0.04 to 3). </p> <p>For the outcome of 'no global improvement between 2 and 10 weeks', no clear differences were found when very high dose was compared with standard higher dose (n = 58, 1 RCT, RR 0.78, 95% CI 0.5 to 1.3), and high dose (n = 255, 4 RCTs, RR 1.09, 95% CI 0.9 to 1.3). Mean change scores comparing very high dose with standard higher dose and high dose were equally equivocal. The numbers of people needing additional sedation was not significantly different when very high dose was compared with standard higher dose (n = 58, 1 RCT, RR 0.7, 95% CI 0.3 to 1.6) or high dose (n = 115, 2 RCTs, RR 0.94, 95% CI 0.6 to 1.5). </p> </section> <section id="CD001951-sec-0137"> <h5 class="title">6.4 Mental state/behaviour</h5> <p>Very high doses were no different to any other doses for various measures of mental state/behaviour. For the outcome of 'no clinically important change in psychotic symptoms between three days and two weeks,' very high doses were not significantly different to standard higher doses (n = 20, 1 RCT, RR 0.33, 95% CI 0.04 to 2.7). There was also no significant difference in changes in psychotic symptoms when very high dose were compared with high dose (n = 92, 1 RCT, RR 1.18, 95% CI 0.9 to 1.5). Mean change scores on rating of mental state were also equivocal for a comparison of very high dose versus high dose. Finally, agitation was equally common for people given very high dose when compared with both standard higher dose (n = 58, 1 RCT, RR 0.7, 95% CI 0.3 to 1.6) and high dose (n = 115, 2 RCTs, RR 0.94, 95% CI 0.6 to 1.5). </p> </section> <section id="CD001951-sec-0138"> <h5 class="title">6.5 Adverse effects</h5> <p>Acute dystonia was as common for people allocated very high dose as for people given standard higher dose (n = 63, 1 RCT, RR 1.45, 95% CI 0.9 to 2.5). However, when compared with standard lower dose, very high doses did not cause more clinically significant EPAEs (n = 86, 2 RCTs, RR 1.42, 95% CI 0.9 to 2.2). When very high dose was compared with high dose, studies found no difference (n = 114, 2 RCTs, RR 0.97, 95% CI 0.7 to 1.4). Mean scores where very high dose was compared with standard higher dose or high dose, were equivocal and uninformative. Use of drugs to counter parkinsonism was as common for those allocated very high dose as for people given standard lower doses (n = 70, 1 RCT, RR 1.25, 95% CI 0.8 to 2) and high dose (n = 114, 2 RCTs, RR 0.89, 95% CI 0.7 to 1.1). Akathisia was common, but no more so for people taking very high dose compared with high dose (n = 57, 1 RCT, RR 1.4, 95% CI 0.7 to 2.7). </p> <p>Finally, postural hypotension was not common and had the same risk of occurrence for people taking very high doses and those given standard higher dose (n = 63, 1 RCT, RR 1.43, 95% CI 0.1 to 34). </p> </section> </section> <section id="CD001951-sec-0139"> <h4 class="title">7. DOSES: 7. COMBINED HIGH AND VERY HIGH DOSES (&gt; 15 mg/day) versus OTHER DOSES</h4> <section id="CD001951-sec-0140"> <h5 class="title">7.1 Leaving the study early</h5> <p>One study compared doses above 15 mg/day with standard higher doses (&gt; 7.5 to 15 mg/day). There was no significant difference between groups in either early attrition (1 to 2 days) or late (2 to 10 weeks) (Analysis 7.1). </p> </section> <section id="CD001951-sec-0141"> <h5 class="title">7.2 Adverse effects</h5> <p>There was no significant difference in rates of EPSE between the combined high and very high group and the standard higher group (Analysis 7.1). </p> </section> </section> <section id="CD001951-sec-0142"> <h4 class="title">8. PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</h4> <section id="CD001951-sec-0143"> <h5 class="title">8.1 Leaving the study early</h5> <p>Very low plasma levels (&gt; 3.5 to 7 ng/mL) resulted in fewer people leaving the studies early when compared to medium plasma levels (&gt; 7.0 to 16.5 ng/mL), but this did reach statistical significance (n = 128, 2 RCTs, RR 0.61, 95% CI 0.4 to 1.1). There was no clear difference when very low plasma levels were compared with high levels (&gt; 16.5 ng/mL) (n = 70, 1 RCT, RR 0.96, 95% CI 0.4 to 2.4). </p> </section> <section id="CD001951-sec-0144"> <h5 class="title">8.2 Global state</h5> <p>One study monitored 'no clinically significant improvement in global state' (n = 65) and when very low plasma levels were compared with medium levels (&gt; 7.0 to 16.5 ng/mL), the trialists found no difference (RR 0.8, 95% CI 0.3 to 1.9) (<a href="./references#CD001951-bbs2-0018" title="ChouJC , DouyonR , CzoborP , VolavkaJ , CooperTB . Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Research1998;81(1):51‐5. CzoborP , VolavkaJ . Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Comprehensive Psychiatry1996;37(3):205‐15. CzoborP , VolavkaJ . Positive and negative symptoms: is their change related?. Schizophrenia Bulletin1996;22(4):577‐90. VolavkaJ , CooperTB , CzoborP , MeisnerM . Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. Psychopharmacology Bulletin1996;32(1):75‐9. VolavkaJ , CooperTB , CzoborP , MeisnerM . Haloperidol plasma levels and clinical effects. Psychopharmacology Bulletin1995;31:536. VolavkaJ , CooperTB , CzoborP , MeisnerM . Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Archives of General Psychiatry1995;52(10):837‐45. ">Volavka 1995</a>). </p> </section> <section id="CD001951-sec-0145"> <h5 class="title">8.3 Mental state/behaviour</h5> <p>One study looked at 'significant response in positive symptoms' between very low and medium plasma level but found no significant differences (<a href="./references#CD001951-fig-0096" title="">Analysis 8.3</a>). </p> </section> <section id="CD001951-sec-0146"> <h5 class="title">8.4 Adverse effects</h5> <p>Very low plasma levels resulted in fewer clinically significant EPEAs than medium levels (n = 128, 2 RCTs, RR 0.63, 95% CI 0.5 to 0.8, NNTH 3, 95% CI 2 to 7). When the same very low levels were compared with high plasma levels, no clear differences were found (n = 70, 1 RCT, RR 0.8, 95% CI 0.5 to 1.2). </p> </section> </section> <section id="CD001951-sec-0147"> <h4 class="title">9. PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</h4> <section id="CD001951-sec-0148"> <h5 class="title">9.1 Leaving the study early</h5> <p>Compared with very low plasma levels (&gt; 1.4 to 3.5 ng/mL), medium levels did not promote study attrition (n = 128, 2 RCTs, RR 1.63, 95% CI 0.9 to 3). This also applied to comparisons with high plasma levels (&gt; 16.5 ng/mL), although results were heterogeneous (n = 149, 2 RCTs, RR 1.1, 95% CI 0.6 to 2.1, heterogeneous P value = 0.074). </p> </section> <section id="CD001951-sec-0149"> <h5 class="title">9.2 Global state</h5> <p>Medium plasma levels did not result in different rates of global improvement when compared with either very low plasma levels (n = 65, 1 RCT, RR 0.80, 95% CI 0.3 to 1.9) or high plasma levels (n = 92, 1 RCT, RR 1.57, 95% CI 0.8 to 3.1). </p> </section> <section id="CD001951-sec-0150"> <h5 class="title">9.3 Mental state/behaviour</h5> <p>Two studies looked at significant response in positive symptoms between medium and low plasma levels and found no significant differences (<a href="./references#CD001951-fig-0100" title="">Analysis 9.3</a>). </p> </section> <section id="CD001951-sec-0151"> <h5 class="title">9.4 Adverse effects</h5> <p>Clinically significant EPAEs were more common for those allocated to medium plasma levels compared with people in a very low plasma level group (n = 128, 2 RCTs, RR 1.59, 95% CI 1.2 to 2.1, NNTH 3, 95% CI 2 to 7). There was no clear difference for those in a medium plasma level group compared with a high level group (n = 59, 1 RCT, RR 1.28, 95% CI 0.9 to 1.8). </p> </section> </section> <section id="CD001951-sec-0152"> <h4 class="title">10. PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</h4> <section id="CD001951-sec-0153"> <h5 class="title">10.1 Leaving the study early</h5> <p>Compared with both very low plasma levels (&gt; 1.4 to 3.5 ng/mL), high plasma levels did not affect study attrition (n = 70, 1 RCT, RR 1.04, 95% CI 0.4 to 2.6), neither did medium levels (&gt; 7 to 16.5 ng/mL) (n = 149, 2 RCTs, RR 0.91, 95% CI 0.5 to 1.7, heterogeneous P value = 0.074). </p> </section> <section id="CD001951-sec-0154"> <h5 class="title">10.2 Global response</h5> <p>One small study (n = 92) reported that there was no difference for those allocated to high levels compared with medium plasma levels (RR 1.18, 95% CI 0.9 to 1.5). </p> </section> <section id="CD001951-sec-0155"> <h5 class="title">10.3 Adverse effects</h5> <p>Over half of people given haloperidol, irrespective of plasma level, had significant EPAEs (high levels versus very low levels: n = 70, 1 RCT, RR 1.25, 95% CI 0.8 to 2; high levels versus medium levels: n = 59, 2 RCTs, RR 0.8, 95% CI 0.5 to 1.1). </p> </section> </section> <section id="CD001951-sec-0156"> <h4 class="title">11. Sensitivity analyses</h4> <p>There were no data to undertake analyses separately for people in their first episode of illness. As regards use of operational diagnostic criteria, only <a href="./references#CD001951-bbs2-0001" title="CurtisCE , MannM , PiscaniK , BurrG , HitzemannRJ , HirschowitzJ . A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami. 1995. ">Curtis 1995</a>, <a href="./references#CD001951-bbs2-0002" title="DonlonPT , HopkinJT , TupinJP , WicksJJ , WahbaM , MeadowA . Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens. Archives of General Psychiatry1980;6:691‐5. WahbaM , DonlonPT , MeadowA . Cognitive changes in acute schizophrenia with brief neuroleptic treatment. American Journal of Psychiatry1981;138(10):1307‐10. ">Donlon 1980</a> and <a href="./references#CD001951-bbs2-0015" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9(8):401‐12. ">Simpson 1967</a> did not use operational criteria that were clearly described. Where these trials contributed to outcomes in which meta‐analysis had taken place, in no case did they alter the final result to an important extent. When these trials were the sole contributor to an outcome ‐ for example <a href="./references#CD001951-fig-0096" title="">Analysis 8.3</a> or <a href="./references#CD001951-fig-0100" title="">Analysis 9.3</a> in the case of <a href="./references#CD001951-bbs2-0001" title="CurtisCE , MannM , PiscaniK , BurrG , HitzemannRJ , HirschowitzJ . A neuroendocrine method of antipsychotic dose reduction in schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20‐25; Miami. 1995. ">Curtis 1995</a> ‐ removal of these data deleted the outcome as a whole. However, there is no evidence that trials using operational criteria to diagnose people with schizophrenia have substantially different results from trials that imply that such stipulated criteria were not employed. Finally we were not confident that trials specifically included people whose illness would be recognised as treatment resistant, and therefore we did not undertake a sensitivity analysis. </p> </section> <section id="CD001951-sec-0157"> <h4 class="title">12. Publication bias</h4> <p>There was an insufficient number of trials per comparison (maximum of five trials) to conduct a valid funnel plot to examine for possible publication bias. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001951-sec-0158" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001951-sec-0158"></div> <section id="CD001951-sec-0159"> <h3 class="title" id="CD001951-sec-0159">Summary of main results</h3> <section id="CD001951-sec-0160"> <h4 class="title">1. DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES</h4> <p><a href="./references#CD001951-bbs2-0004" title="KapurS , ZipurskyR , JonesC , RemingtonG , HouleS . Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double‐blind PET study of first‐episode schizophrenia. American Journal of Psychiatry2000;4:514‐20. ">Kapur 2000</a> compared ultra low dose to low dose (&gt; 1.5 to 3 mg/day) and found no differences in terms of leaving the study early (both treatments were very acceptable), global measures of outcome, mental state and adverse effects. For a study involving 26 people, it would have been surprising if any outcomes had suggested a clear difference in groups, but that several favoured the ultra low dose group, even if they did not reach conventional levels of statistical significance. This suggests that this question could be further investigated. </p> </section> <section id="CD001951-sec-0161"> <h4 class="title">2. DOSES: 2. LOW DOSE (&gt; 1.5 to 3 mg/day) versus OTHER DOSES</h4> <p><a href="./references#CD001951-bbs2-0012" title="OosthuizenP , EmsleyR , TurnerHJ , KeyterN . A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first‐episode psychosis. International Journal of Neuropsychopharmacology2004;7(2):125‐31. [MEDLINE: 15003147] ">Oosthuizen 2004</a> compared low dose to standard higher dose (&gt; 7.5 to 15 mg/day). Measures of efficacy of intervention such as PANSS and CGI were similar between groups, the Calgary Depression Rating Scale was also unequivocal as was lorazepam use for agitation. Some of the adverse effects measures ‐ such as mean dose of orphenadrine used and mean prolactin level ‐ were significantly higher in the high dose group (&gt; 15 to 35 mg/day) suggesting better tolerability of low dose. Rates of attrition, dystonia, dyskinesia and akathisia all favoured use of a low dose though results for these measures were not statistically significant. This study involved 40 participants and was, therefore, underpowered to assess efficacy and tolerability in all areas adequately. No other studies investigated this comparison. </p> </section> <section id="CD001951-sec-0162"> <h4 class="title">3. DOSES: 3. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES</h4> <p>The standard lower dose was, generally, more acceptable than any of the higher doses, as measured in terms of leaving the study early (<a href="./full#CD001951-tbl-0001">summary of findings Table for the main comparison</a>). However, no findings reached conventional levels of statistical significance but all comparisons involved small numbers (maximum 191). Considering the importance of this question, it would seem that more investigation is justified. </p> <p>Standard lower dose was as effective, in terms of global state and mental state, as standard higher dose (&gt; 7.5 to 15 mg/day) and high dose (&gt; 15 to 35 mg/day), but again, the numbers involved in these comparisons were small (maximum 126). This lack of difference is striking given the tendency in clinical practice to increase the dose of people who do not respond, or to utilise high doses from the start of treatment. The finding is probably widely applicable, given that global improvement was defined in a variety of ways across studies. Considering the potential for the introduction of bias into these outcomes, this finding should only be considered as hypothesis‐generating. </p> <p>Standard lower dose consistently resulted in fewer people experiencing EPAEs, when compared with higher doses. In the comparison involving most people (n = 144), this did reach statistical significance with an NNTB of three. This is an important finding given the frequent use of the latter dose range in comparative trials of new antipsychotic agents and in clinical practice. It is also interesting to note that this finding had some preliminary evidence as early as 1967 (<a href="./references#CD001951-bbs2-0015" title="SimpsonGM , AngusJWS , EdwardsJG . A controlled study of haloperidol in chronic schizophrenia. Current Therapeutic Research1967;9(8):401‐12. ">Simpson 1967</a>). Unfortunately, this was not re‐examined in a high‐quality study until 1984 (<a href="./references#CD001951-bbs2-0027" title="GarverDL , KellyK , FriedKA , MagnussonM , HirschowitzJ . Drug response patterns as a basis of nosology for the mood‐incongruent psychoses (the schizophrenias). Psychological Medicine1988;18:873‐85. MavroidisML , GarverDL , KanterDR , HirschowitzJ . Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacology Bulletin1985;21(1):62‐5. [MEDLINE: 3983340] MavroidisML , KanterDR , HirschowitzJ , GarverDL . Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology1983;81(4):354‐6. ">Garver 1984</a>), and was not reported appropriately in a study until 1991 (<a href="./references#CD001951-bbs2-0009" title="McEvoyJP , HogartyGE , SteingardS . Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold. Archives of General Psychiatry1991;48(8):739‐45. McEvoyJP , SchoolerNR , WilsonWH . Predictors of therapeutic response to haloperidol in acute schizophrenia. Psychopharmacology Bulletin1991;27(2):97‐101. ">McEvoy 1991</a>). Nevertheless, despite this favourable result for the standard lower dose, nearly half of the people given standard lower dose either experienced these distressing adverse effects or left the study early. </p> </section> <section id="CD001951-sec-0163"> <h4 class="title">4. DOSES: 4. STANDARD HIGHER DOSE (7.5 to 15 mg/day) versus OTHER DOSES</h4> <p>All relevant studies were small and, even when combined, the totals amounted to no more than 188 people. </p> <p>Standard higher dose did not result in people leaving the short studies early, when compared with standard lower dose (&gt; 3 to 7.5 mg/day), high dose (&gt; 15 to 35 mg/day) or very high dose (&gt; 35 mg/day). There were also no clear differences for global state or mental state/behaviour. Most data were reported for the comparison of standard higher dose with high dose at 2 to 10 weeks (n = 106), for 'no clinically important improvement in global state'. Numbers in groups were evenly balanced, with more than one‐third of participants not showing any important degree of improvement. The fact that there was no difference in response between dose groups may be suggestive that dose level is less important, for global state and mental state outcomes, than just taking the antipsychotic. </p> <p>While no comparisons found differences in the few adverse effects reported, there were the suggestions, consistent with the other data in this review, that higher doses led to more adverse effects. </p> </section> <section id="CD001951-sec-0164"> <h4 class="title">5. DOSES: 5. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</h4> <p>These set of comparisons contain some of the highest numbers of participants in this review (maximum 312). </p> <p>High dose haloperidol seems as acceptable, in terms of leaving these short studies early, as standard lower dose (&gt; 3 to 7.5 mg/day) (n = 191), standard higher (&gt; 7.5 to 15 mg/day) (n = 188) and very high doses (&gt; 35 mg/day) (n = 312). </p> <p>For outcomes relevant to mental state/behaviour, the numbers in each comparison were low and no differences were discernible. It does seem surprising that so little research reporting useful data has been undertaken in this key area. </p> <p>Direct comparisons for measures of global state found no differences when high dose was compared with standard lower, standard higher dose and very high doses. The risk of needing additional sedation was greater for people given high dose compared with standard lower (n = 144, NNTH 3), but not with standard higher dose, and very high doses. This must be seen as an advantage of the standard lower dose compared with the high dose. High doses also resulted in more people experiencing EPAEs or needing drugs to counter parkinsonism compared with standard lower doses (n = 144, NNTH 3), but the same levels as very high doses (n = 134). Akathisia was as common for people allocated to high dose as people allocatedtovery high dose. </p> <p>There is no evidence that a high dose is better than standard low for mental state/global state outcomes, and the findings favouring standard low dose for adverse effect outcomes is compelling. </p> </section> <section id="CD001951-sec-0165"> <h4 class="title">6. DOSES: 6. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</h4> <p>Very high doses did not disproportionately cause people to leave studies before completion. Very high doses were as clinically effective for global state/mental state outcomes as standard higher dose (&gt; 7.5 to 15 mg/day) (n = 58), and high dose (&gt; 15 to 35 mg/day) (n = 255). </p> <p>Several movement disorder adverse effects were not significantly more common for people given very high doses compared with high dose (n = 117), standard higher dose (n = 63) and even standard lower dose (&gt; 3 to 7.5 mg/day) (n = 86). This is a somewhat surprising result considering the consistent findings thus far in this review ‐ where higher doses of haloperidol do result in more adverse effects, and is difficult to explain. </p> </section> <section id="CD001951-sec-0166"> <h4 class="title">7. DOSES: 7. COMBINED HIGH AND VERY HIGH DOSE (&gt; 15 mg/day) versus OTHER DOSES</h4> <p><a href="./references#CD001951-bbs2-0008" title="Louza NetoMR , Muller SpahnF , RutherE , SchererJ . Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients. Pharmacopsychiatry1988;21(5):226‐31. [MEDLINE: 3227054] ">Louza 1988</a> found no differences in attrition rates or EPSE between more than 15 mg/day and standard higher dose (&gt; 7.5 to 15 mg/day). This was a small, single study comparison (n = 20). </p> </section> <section id="CD001951-sec-0167"> <h4 class="title">8. PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</h4> <p>Very low plasma levels (&gt; 3.5 to 7 ng/mL) resulted in fewer people leaving the studies early when compared to medium plasma levels (&gt; 7.0 to 16.5 ng/mL), but this did not quite reach conventional levels of statistical significance (n = 128). When compared with medium plasma levels, very low plasma levels were not clearly different for the outcome of 'no clinically significant improvement in global state' (n = 65). As regards adverse effects, however, very low plasma levels resulted in fewer clinically significant EPAEs than medium levels (n = 128, NNTH 3). This finding was not replicated when the very low levels were compared with high plasma levels (&gt; 16.5 ng/mL), but this may have been because of the low power of this comparison (n = 70). </p> </section> <section id="CD001951-sec-0168"> <h4 class="title">9. PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</h4> <p>Compared with very low plasma levels (&gt; 1.4 to 3.5 ng/mL) (n = 128), and high plasma levels (&gt; 16.5 ng/mL) (n = 149), medium levels did not clearly promote study attrition or encourage different rates of global improvement. </p> <p>Clinically significant EPAEs were more common for those allocated to medium plasma levels compared with people in a very low plasma level group (n = 128, NNTH 3), but no different when compared with the high plasma level group (n = 59). This could have been a function of power and the consistent finding is that lower levels/doses of haloperidol do lead to fewer adverse effects. </p> </section> <section id="CD001951-sec-0169"> <h4 class="title">10. PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</h4> <p>Compared with both very low plasma levels (&gt; 1.4 to 3.5 ng/mL) (n = 70) high plasma levels did not clearly affect study attrition, or when compared with medium plasma levels (&gt; 7 to 16.5 ng/mL) (n = 149). There was no difference for those allocated to high levels compared with medium plasma levels (n = 92) for global state outcomes, and no differences for adverse effects. However, over half of the participants given haloperidol, irrespective of plasma level, had significant EPAEs (versus very low plasma levels, n = 70; versus medium plasma levels, n = 59). </p> <p>Even if the global and mental state changes do not seem greatly sensitive to dose, haloperidol is a common cause of adverse effects and the latter tend to be more common with higher dose/plasma level. </p> </section> </section> <section id="CD001951-sec-0170"> <h3 class="title" id="CD001951-sec-0170">Overall completeness and applicability of evidence</h3> <p>This study benefited from extensive searches of the worldwide literature regarding haloperidol dosage. Some of the non‐English studies may not have been included without such extensive searches (<a href="./references#CD001951-bbs2-0006" title="KlieserE , LehmannE . Experimental comparison of the effectivity of individually adapted and standardized dosages of haloperidol. Neuropsychobiology1987;18(3):122‐6. KlieserE , LehmannE . Experimental comparison of the efficacy of standardized haloperidol treatment and adequate individual dosages in acute schizophrenic states. Fortschritte der Neurologie Psychiatrie1992;3:126‐9. ">Klieser 1987</a>; <a href="./references#CD001951-bbs2-0007" title="LiangS . Comparison of therapeutic effects between haloperidol and insulin coma for schizophrenia and the optimal blood level of haloperidol. Chinese Journal of Neurology and Psychiatry1987;20(1):43‐8. ">Liang 1987</a>). Another major strength was that all comparisons were restricted to randomised studies of the same drug, which has not been the case with previous reviews (<a href="./references#CD001951-bbs2-0048" title="BaldessariniRJ , KatzB , CottonP . Dissimilar dosing with high‐potency and low‐potency neuroleptics. American Journal of Psychiatry1984;141(6):748‐52. ">Baldessarini 1984</a>; <a href="./references#CD001951-bbs2-0054" title="BolliniP , PampallonaS , OrzaMJ , AdamasME , ChalmersTC . Antipsychotic drugs: is more worse? A meta‐analysis of the published randomised control trials. Psychological Medicine1994;24:307‐16. ">Bollini 1994</a>). This should significantly reduce the potential for bias introduced by using differing measures for the various outcomes studied. </p> <p>A major weakness of this study was that for several outcomes there was either minimal or no data from high‐quality randomised trials. This resulted in many findings being prone to type II errors (a masking of a real effect by wide CIs), and several important hypotheses being unanswered. </p> </section> <section id="CD001951-sec-0171"> <h3 class="title" id="CD001951-sec-0171">Quality of the evidence</h3> <p>The quality of included studies was generally poor, with authors not describing the randomisation process, allocation concealment and blinding (<a href="#CD001951-fig-0003">Figure 3</a>; <a href="#CD001951-fig-0004">Figure 4</a>). This could mean that even these few results are prone to biases and an overestimate of effect. Poor reporting of the process and outcomes of the trials was common. We excluded many studies due to a lack of information about the number of people randomised to various treatment arms. </p> <p>The number and size of trials was particularly poor for the dose range of primary interest (low dose &gt; 1.5 to 3 mg/day) and the lowest dose range (ultra low dose &gt; 0.25 to 1.5 mg/day). Only one small study (n = 26) compared the lowest two groups (<a href="./references#CD001951-bbs2-0004" title="KapurS , ZipurskyR , JonesC , RemingtonG , HouleS . Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double‐blind PET study of first‐episode schizophrenia. American Journal of Psychiatry2000;4:514‐20. ">Kapur 2000</a>), and no study compared the primary dose range of interest to the next highest dose range. One further study (n = 40) compared low dose and standard higher dose (&gt; 7.5 to 15 mg/day) (<a href="./references#CD001951-bbs2-0012" title="OosthuizenP , EmsleyR , TurnerHJ , KeyterN . A randomised, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first‐episode psychosis. International Journal of Neuropsychopharmacology2004;7(2):125‐31. [MEDLINE: 15003147] ">Oosthuizen 2004</a>). </p> </section> <section id="CD001951-sec-0172"> <h3 class="title" id="CD001951-sec-0172">Potential biases in the review process</h3> <p>While the authors made every effort to avoid publication bias, it remains possible that not all relevant studies have been identified as yet. The Cochrane Register of studies could still represent a biased sample of trials. However, we consider that a large unpublished trial in this area is implausible and that we are more likely to have overlooked other small studies. </p> <p>We do not think that we have biased the review process by holding prior opinions and having seen past reviews. However, we have not tested this in undertaking the work. </p> </section> <section id="CD001951-sec-0173"> <h3 class="title" id="CD001951-sec-0173">Agreements and disagreements with other studies or reviews</h3> <p>A systematic review of randomised trials of the maintenance phase of schizophrenia reached a similar conclusion to that made in this review in 2002 (<a href="./references#CD001951-bbs2-0122" title="WaraichPS , AdamsCE , RoqueM , HamillKM , MartiJ . Haloperidol dose for the acute phase of schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD001951; PUBMED: 12137638] ">Waraich 2002</a>), and by others even longer ago (<a href="./references#CD001951-bbs2-0054" title="BolliniP , PampallonaS , OrzaMJ , AdamasME , ChalmersTC . Antipsychotic drugs: is more worse? A meta‐analysis of the published randomised control trials. Psychological Medicine1994;24:307‐16. ">Bollini 1994</a>); they concluded that there is no benefit in administering doses higher than 375 mg/day of chlorpromazine or the equivalent of such a dose when using other antipsychotics (about 7.5 mg/day of haloperidol). Despite this, many studies have been conducted since using much higher doses than 7.5 mg/day of haloperidol (<a href="./references#CD001951-bbs2-0092" title="KennedyE , SongF , HunterR , ClarkeA , GilbodyS . Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 2. [DOI: 10.1002/14651858.CD000440] ">Kennedy 2002</a>; <a href="./references#CD001951-bbs2-0095" title="LeuchtS , Pitschel‐WalzG , AbrahamD , KisslingW . Efficacy and extra‐pyramidal side‐effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta‐analysis of randomised controlled trials. Schizophrenia Research1999;35:51‐68. ">Leucht 1999</a>; <a href="./references#CD001951-bbs2-0109" title="RosenheckMD , PerlickD , BinghamS , Liu‐MaresW , CollinsJ , WarrenS , et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA2003;290(20):2693‐702. ">Rosenheck 2003</a>; <a href="./references#CD001951-bbs2-0113" title="SrisurapanontM , DisayavanishC , TaimkaewK . Quetiapine for schizophrenia. Cochrane Database of Systematic Reviews2002, Issue 1. [DOI: 10.1002/14651858.CD000967.pub2] ">Srisurapanont 2002</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001951-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (from results of 2010 search only)." data-id="CD001951-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (from results of 2010 search only).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (2002 review)." data-id="CD001951-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram (2002 review).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001951-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001951-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks)." data-id="CD001951-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 2 Global state: no clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 2 Global state: no clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 3 Global state: use of adjunctive medication for sedation (2‐10 weeks)." data-id="CD001951-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 3 Global state: use of adjunctive medication for sedation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 4 Mental state/behaviour: clinically significant agitation (2‐10 weeks)." data-id="CD001951-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 4 Mental state/behaviour: clinically significant agitation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 5 Adverse effects: clinically significant EPSE (2‐10 weeks)." data-id="CD001951-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 5 Adverse effects: clinically significant EPSE (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 6 Adverse effects: use of antiparkinsonism drugs (2‐10 weeks)." data-id="CD001951-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES, Outcome 6 Adverse effects: use of antiparkinsonism drugs (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks)." data-id="CD001951-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 2 Global state: 1. No clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 2 Global state: 1. No clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 3 Global state: 2. Use of adjunctive medication for sedation (2‐10 weeks)." data-id="CD001951-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 3 Global state: 2. Use of adjunctive medication for sedation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0014"> <p> <div class="table" id="CD001951-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus standard higher dose (7.5‐15 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard high dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = 0.23, d.f = 37, p = 0.82</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 4 Global state: 3. CGI score at endpoint (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0015"> <p> <div class="table" id="CD001951-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus standard higher dose (&gt; 7.5‐15 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = ‐0.01, d.f = 37, p = 99</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 5 Global state: 4. Mean dose of lorazepam (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0015">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 6 Mental state/behaviour: 1. Clinically significant agitation (2‐10 weeks)." data-id="CD001951-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 6 Mental state/behaviour: 1. Clinically significant agitation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0017"> <p> <div class="table" id="CD001951-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>versus standard higher dose (&gt; 7.5‐15 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 7 Mental State/behaviour: 2. PANNS general endpoint score (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0017">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 8 Mental state/behaviour: 3. PANSS positive endpoint score." data-id="CD001951-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 8 Mental state/behaviour: 3. PANSS positive endpoint score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0019"> <p> <div class="table" id="CD001951-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>versus standard higher dose (&gt; 7.5‐15 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 9 Mental state/behaviour: 4. PANNS negative endpoint score (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0019">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0020"> <p> <div class="table" id="CD001951-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus standard higher dose (&gt; 7.5‐15 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standrad high dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = 0.8, d.f = 38, p = 0.42</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 10 Mental state/behaviour: 5. Calgary Depression Rating Scale endpoint score (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 11 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 11 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 12 Adverse effects: 2a. Use of any antiparkinsonism drugs (2‐10 weeks)." data-id="CD001951-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 12 Adverse effects: 2a. Use of any antiparkinsonism drugs (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0023"> <p> <div class="table" id="CD001951-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus standard higher dose (&gt;7.5‐15mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>555.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>943.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2261.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = 2.5, d.f = 37, p = 0.016</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 13 Adverse effects: 2b. Mean dose of orphenadrine (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 14 Adverse effects: 3. Dystonic reaction (duration unclear)." data-id="CD001951-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 14 Adverse effects: 3. Dystonic reaction (duration unclear). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 15 Adverse effects: 4. Dyskinesia (duration unclear)." data-id="CD001951-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 15 Adverse effects: 4. Dyskinesia (duration unclear). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 16 Adverse effects: 5. Akathisia (duration unclear)." data-id="CD001951-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 16 Adverse effects: 5. Akathisia (duration unclear). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0027"> <p> <div class="table" id="CD001951-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean (ng/ml)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus standard higher dose (&gt; 7.5‐15 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = ‐0.38, d.f = 9, p = 0.7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = ‐3.49, d.f = 10, p = 0.006</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES, Outcome 17 Adverse effects: 6. Prolactin at endpoint (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0027">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks)." data-id="CD001951-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 2 Global state: 1. No clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 2 Global state: 1. No clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 3 Global state: 2. Use of adjunctive medication for sedation." data-id="CD001951-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 3 Global state: 2. Use of adjunctive medication for sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 4 Mental state/behaviour: clinically significant agitation (2‐10 weeks)." data-id="CD001951-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 4 Mental state/behaviour: clinically significant agitation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 5 Mental state/behaviour: no psychotic symptoms (2‐10 weeks)." data-id="CD001951-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 5 Mental state/behaviour: no psychotic symptoms (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 6 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 6 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 7 Adverse effects: 2. Use of any antiparkinsonism drugs (2‐10 weeks)." data-id="CD001951-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 7 Adverse effects: 2. Use of any antiparkinsonism drugs (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 8 Adverse effects: 3. Specific adverse effects‐blurred vision (&lt; 2 weeks)." data-id="CD001951-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES, Outcome 8 Adverse effects: 3. Specific adverse effects‐blurred vision (&lt; 2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 1 Mortality (3 days‐2 weeks)." data-id="CD001951-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 1 Mortality (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 2 Leaving the study early (day 1‐2)." data-id="CD001951-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 2 Leaving the study early (day 1‐2). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 3 Leaving the study early: 1. By between 3 and 14 days." data-id="CD001951-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 3 Leaving the study early: 1. By between 3 and 14 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 4 Leaving the study early: 2. By between 2 and 10 weeks." data-id="CD001951-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 4 Leaving the study early: 2. By between 2 and 10 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 5 Global state: 1. No clinically significant response (3 days‐2 weeks)." data-id="CD001951-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 5 Global state: 1. No clinically significant response (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 6 Global state: 2. No clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 6 Global state: 2. No clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 7 Global state: 3. Mean change CGI." data-id="CD001951-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 7 Global state: 3. Mean change CGI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 8 Global state: 4. Use of adjunctive medication for sedation." data-id="CD001951-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 8 Global state: 4. Use of adjunctive medication for sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0044"> <p> <div class="table" id="CD001951-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus low dose (&gt; 1.5‐3 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard high dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = 0.23, d.f = 37, p = 0.82</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 9 Global state: 5. CGI score at endpoint (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0044">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0045"> <p> <div class="table" id="CD001951-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus low dose (&gt; 1.5‐3 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = ‐0.01, d.f = 37, p = 99</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 10 Global state: 6. Mean dose of lorazepam (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0045">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 11 Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days‐2 weeks)." data-id="CD001951-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 11 Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 12 Mental state/behaviour: 2. Clinically significant agitation (2‐10 weeks)." data-id="CD001951-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 12 Mental state/behaviour: 2. Clinically significant agitation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0048"> <p> <div class="table" id="CD001951-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>versus low dose (&gt; 1.5‐3 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 13 Mental State/behaviour: 3. PANNS general endpoint score (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0048">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 14 Mental state/behaviour: 3. PANSS positive endpoint score." data-id="CD001951-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 14 Mental state/behaviour: 3. PANSS positive endpoint score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0050"> <p> <div class="table" id="CD001951-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study Group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>versus low dose (&gt; 1.5‐3 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 15 Mental state/behaviour: 4. PANNS negative endpoint score (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0050">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0051"> <p> <div class="table" id="CD001951-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>versus low dose (&gt; 1.5‐3 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standrad high dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>low dose (&gt;1.5‐3mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 16 Mental state/behaviour: 5. Calgary Depression Rating Scale endpoint score (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0051">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 17 Adverse effects: 1. Acute dystonia (3 days‐2 weeks)." data-id="CD001951-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 17 Adverse effects: 1. Acute dystonia (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 18 Adverse effects: dystonic reaction (duration unclear)." data-id="CD001951-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 18 Adverse effects: dystonic reaction (duration unclear). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 19 Adverse effects: dyskinesia (duration unclear)." data-id="CD001951-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.19</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 19 Adverse effects: dyskinesia (duration unclear). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 20 Adverse effects: akathisia (duration unclear)." data-id="CD001951-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.20</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 20 Adverse effects: akathisia (duration unclear). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 21 Adverse effects: 2a. Clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.21</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 21 Adverse effects: 2a. Clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0057"> <p> <div class="table" id="CD001951-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus low dose (&gt; 1.5‐3 mg/day)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1967.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2261.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>555.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>943.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = 2.5, d.f = 37, p = 0.016</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.22</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 22 Adverse effects: 2b. Mean dose of orphenadrine (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0057">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 23 Adverse effects: 3. Mean score/change in EPS." data-id="CD001951-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.23</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 23 Adverse effects: 3. Mean score/change in EPS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-004-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-004-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 24 Adverse effects: 4. Postural hypotension (3 days‐2 weeks)." data-id="CD001951-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.24</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 24 Adverse effects: 4. Postural hypotension (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-004-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0060"> <p> <div class="table" id="CD001951-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mean (ng/ml)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SD</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>versus low dose (&gt; 1.5‐3 mg/day) </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = ‐3.49, d.f = 10, p = 0.006</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oosthuizen 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low dose (&gt;1.5‐3mg/day)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>t = ‐0.38, d.f = 9, p = 0.7</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.25</div> <div class="figure-caption"> <p>Comparison 4 DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES, Outcome 25 Adverse effects: 6. Prolactin at endpoint (skewed data). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0060">Navigate to figure in review</a></div> </div> <div class="figure" id="CD001951-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks)." data-id="CD001951-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 1 Leaving the study early (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 2 Global state: 1. No clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 2 Global state: 1. No clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 3 Global state: 2. Mean change CGI." data-id="CD001951-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 3 Global state: 2. Mean change CGI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 4 Global state: 3a. Use of adjunctive medication for sedation." data-id="CD001951-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 4 Global state: 3a. Use of adjunctive medication for sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 5 Global state: 3b. Use of adjunctive medication for sedation (&lt; 2 weeks).." data-id="CD001951-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 5 Global state: 3b. Use of adjunctive medication for sedation (&lt; 2 weeks).. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 6 Global state: 3c. Use of adjunctive medication for sedation (2‐10 weeks).." data-id="CD001951-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 6 Global state: 3c. Use of adjunctive medication for sedation (2‐10 weeks).. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 7 Mental state/behaviour 1: No psychotic symptoms (2‐10 weeks)." data-id="CD001951-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 7 Mental state/behaviour 1: No psychotic symptoms (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 8 Mental state/behaviour: 2. No clinically important change in psychotic symptoms." data-id="CD001951-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.8</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 8 Mental state/behaviour: 2. No clinically important change in psychotic symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 9 Mental state/behaviour: 3. Clinically significant agitation (2‐10 weeks)." data-id="CD001951-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.9</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 9 Mental state/behaviour: 3. Clinically significant agitation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 10 Mental state/behaviour: 4. Mean score ‐ SADS mean score." data-id="CD001951-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.10</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 10 Mental state/behaviour: 4. Mean score ‐ SADS mean score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 11 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.11</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 11 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 12 Adverse effects: 2. Mean score/change in EPS on Simpson Angus scale." data-id="CD001951-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.12</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 12 Adverse effects: 2. Mean score/change in EPS on Simpson Angus scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 13 Adverse effects: 3. Use of any antiparkinsonism drugs (2‐10 weeks)." data-id="CD001951-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.13</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 13 Adverse effects: 3. Use of any antiparkinsonism drugs (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 14 Adverse effects: 4. Akathisia." data-id="CD001951-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.14</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 14 Adverse effects: 4. Akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-005-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-005-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 15 Adverse effects: 3. Specific adverse effects‐blurred vision (&lt; 2 weeks)." data-id="CD001951-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.15</div> <div class="figure-caption"> <p>Comparison 5 DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES, Outcome 15 Adverse effects: 3. Specific adverse effects‐blurred vision (&lt; 2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-005-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 1 Death (3 days‐2 weeks)." data-id="CD001951-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 1 Death (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 2 Leaving the study early: 1. By between 3 and 14 days." data-id="CD001951-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 2 Leaving the study early: 1. By between 3 and 14 days. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 3 Leaving the study early: 2. By between 2 and 10 weeks." data-id="CD001951-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 3 Leaving the study early: 2. By between 2 and 10 weeks. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 4 Global state: 1. No clinically significant response (3 days‐2 weeks)." data-id="CD001951-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 4 Global state: 1. No clinically significant response (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 5 Global state: 2. No clinically significant response (2‐10 weeks)." data-id="CD001951-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 5 Global state: 2. No clinically significant response (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 6 Global state: 3. Mean change CGI." data-id="CD001951-fig-0081" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 6 Global state: 3. Mean change CGI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 7 Global state: 4. Use of adjunctive medication for sedation." data-id="CD001951-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 7 Global state: 4. Use of adjunctive medication for sedation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 8 Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days‐2 weeks)." data-id="CD001951-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.8</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 8 Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 9 Mental state/behaviour: 2. No clinically important change in psychotic symptoms." data-id="CD001951-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.9</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 9 Mental state/behaviour: 2. No clinically important change in psychotic symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 10 Mental state/behaviour: 3. Mean score SADS mean score." data-id="CD001951-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.10</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 10 Mental state/behaviour: 3. Mean score SADS mean score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 11 Mental state/behaviour: 4. Clinically significant agitation (2‐10 weeks)." data-id="CD001951-fig-0086" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.11</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 11 Mental state/behaviour: 4. Clinically significant agitation (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 12 Adverse effects: 1. Acute dystonia (3 days‐2 weeks)." data-id="CD001951-fig-0087" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.12</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 12 Adverse effects: 1. Acute dystonia (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 13 Adverse effects: 2. Clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.13</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 13 Adverse effects: 2. Clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 14 Adverse effects: 3. Mean score/change in EPS Simpson Angus Scale." data-id="CD001951-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.14</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 14 Adverse effects: 3. Mean score/change in EPS Simpson Angus Scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 15 Adverse effects: 4. Use of any antiparkinsonism drugs (2‐10 weeks)." data-id="CD001951-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.15</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 15 Adverse effects: 4. Use of any antiparkinsonism drugs (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 16 Adverse effects: 5. Akathisia." data-id="CD001951-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.16</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 16 Adverse effects: 5. Akathisia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-006-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-006-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 17 Adverse effects: 6. Postural hypotension (3 days‐2 weeks)." data-id="CD001951-fig-0092" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.17</div> <div class="figure-caption"> <p>Comparison 6 DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES, Outcome 17 Adverse effects: 6. Postural hypotension (3 days‐2 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-006-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 DOSES: 6. HIGH AND VERY HIGH DOSES (&gt; 15 mg/day) versus OTHER DOSES, Outcome 1 versus standard higher dose (&gt; 7.5‐15 mg/day)." data-id="CD001951-fig-0093" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 DOSES: 6. HIGH AND VERY HIGH DOSES (&gt; 15 mg/day) versus OTHER DOSES, Outcome 1 versus standard higher dose (&gt; 7.5‐15 mg/day). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 1 Leaving the study early (2‐10 weeks)." data-id="CD001951-fig-0094" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 1 Leaving the study early (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 2 Global state: clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0095" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 2 Global state: clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 3 Mental state: clinically significant response in mental state, positive symptoms (unclear duration)." data-id="CD001951-fig-0096" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 3 Mental state: clinically significant response in mental state, positive symptoms (unclear duration). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 4 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0097" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 4 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 1 Leaving the study early (2‐10 weeks)." data-id="CD001951-fig-0098" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 1 Leaving the study early (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 2 Global state: no clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0099" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 2 Global state: no clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 3 Mental state: clinically significant response in mental state, positive symptoms (duration unclear)." data-id="CD001951-fig-0100" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 3 Mental state: clinically significant response in mental state, positive symptoms (duration unclear). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 4 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0101" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 4 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 1 Leaving the study early (2‐10 weeks)." data-id="CD001951-fig-0102" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 1 Leaving the study early (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 2 Global state: no clinically significant response in global state (2‐10 weeks)." data-id="CD001951-fig-0103" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 2 Global state: no clinically significant response in global state (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001951-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/urn:x-wiley:14651858:media:CD001951:CD001951-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_t/tCD001951-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 3 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks)." data-id="CD001951-fig-0104" src="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS, Outcome 3 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/media/CDSR/CD001951/image_n/nCD001951-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD001951-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design for a trial</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, clearly described, concealed.<br/> Blindness: double, described and tested.<br/> Duration: 8 weeks. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis: schizophrenia.<br/> N = 450.*<br/> Age: any.<br/> Sex: both.<br/> History: acutely unwell. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Haloperidol 1 mg/day. N = 150.<br/> 2. Haloperidol 2.5 mg/day. N = 150. </p> <p>3. Haloperidol 5 mg/day. N = 150.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leaving the study early ‐ reason.</p> <p>Clinical response ‐ no clinically significant response in global state.</p> <p>Extrapyramidal side effects ‐ no clinically significant extrapyramidal side effects, use of anticholinergic medication. </p> <p>Behaviour ‐ agitation, aggression, self harm.</p> <p>Service utilisation ‐ admission, duration of stay.</p> <p>Quality of life ‐ no clinically significant change in quality of life measure.</p> <p>Satisfaction with treatment.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* Powered to be able to identify a difference of about 20% between groups for primary outcome with adequate degree of certainty. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Suggested design for a trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001951-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>DOSES: 2. STANDARD LOWER DOSE (</b> &gt; <b>3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with the acute phase of schizophrenia </p> <p><b>Settings:</b> in hospital </p> <p><b>Intervention:</b> standard lower dose (&gt; 3‐7.5 mg/day) versus other doses </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> STANDARD LOWER DOSE (&gt; 3‐7.5 mg/day) vs. OTHER DOSES</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Leaving the study early (2‐10 weeks) vs. standard higher dose (</b> &gt; <b>7.5‐15 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> <br/> (1 to 257) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.12</b> <br/> (0.01 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Leaving the study early (2‐10 weeks) vs. high dose (</b> &gt; <b>15‐35 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.78</b> <br/> (0.47 to 1.28) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>191<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>2,4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>256 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> <br/> (120 to 328) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>212 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>165 per 1000</b> <br/> (100 to 271) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. standard higher dose (</b> &gt; <b>7.5‐15 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.09</b> <br/> (0.67 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>48<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b> <br/> (375 to 980) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>560 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>610 per 1000</b> <br/> (375 to 980) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global state: 1. No clinically significant response in global state (2‐10 weeks) vs. high dose (</b> &gt; <b>15‐35 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.95</b> <br/> (0.75 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>81<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>2,3,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>760 per 1000</b> <br/> (600 to 952) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>828 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>787 per 1000</b> <br/> (621 to 985) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. standard higher dose (</b> &gt; <b>7.5‐15 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.12</b> <br/> (0.01 to 2.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>64<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>121 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>15 per 1000</b> <br/> (1 to 257) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (1 to 170) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) vs. high dose (</b> &gt; <b>15‐35 mg/day)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.59</b> <br/> (0.45 to 0.78) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>144<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>2,4,8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>769 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>454 per 1000</b> <br/> (346 to 600) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>760 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>448 per 1000</b> <br/> (342 to 593) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Mental state/behaviour: clinically significant agitation (2‐10 weeks)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.93</b> <br/> (0.69 to 1.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>65<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕ ⊝ ⊝ ⊝<br/> <b>very low</b><sup>1,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>698 per 1000</b> <br/> (517 to 945) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Medium risk population</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>750 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>698 per 1000</b> <br/> (517 to 945) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Limitations in design: rated as 'serious' ‐ no trial described randomisation process or tested blinding. </p> <p><sup>2</sup> Imprecision: rated as 'serious' ‐ very small trials. </p> <p><sup>3</sup> Publication bias: rated as 'serious' ‐ two very small trials. </p> <p><sup>4</sup> Limitations in design: rated as 'serious' ‐ no trial described randomisation process and only one tested blinding informally and found it to be ineffective. </p> <p><sup>5</sup> Publication bias: rated as 'serious' ‐ four small trials. </p> <p><sup>6</sup> Imprecision: rated as 'serious' ‐ single small trial. </p> <p><sup>7</sup> Publication bias: rated as 'serious' ‐ single trial. </p> <p><sup>8</sup> Publication bias: rated as 'serious' ‐ three very small trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">STANDARD LOWER DOSE (&gt; 3 to 7.5 mg/day) versus OTHER DOSES for the acute phase of schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/full#CD001951-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: no clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus low dose (&gt;1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: use of adjunctive medication for sedation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state/behaviour: clinically significant agitation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus low dose (1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: clinically significant EPSE (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: use of antiparkinsonism drugs (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">DOSES: 1. ULTRA LOW DOSE (&gt; 0.25 to 1.5 mg/day) versus OTHER DOSES</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.28, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus ultra low doses (&gt; 0.25‐1.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.5 [0.42, 29.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus standard higher group (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.12, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. No clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus ultra low doses (&gt; 0.25‐1.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. Use of adjunctive medication for sedation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus ultra low doses (&gt; 0.25‐1.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 3. CGI score at endpoint (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus standard higher dose (7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 4. Mean dose of lorazepam (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Mental state/behaviour: 1. Clinically significant agitation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 versus ultra low doses (&gt; 0.25‐1.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental State/behaviour: 2. PANNS general endpoint score (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state/behaviour: 3. PANSS positive endpoint score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state/behaviour: 4. PANNS negative endpoint score (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state/behaviour: 5. Calgary Depression Rating Scale endpoint score (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 versus ultra low doses (&gt; 0.25‐1.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 2a. Use of any antiparkinsonism drugs (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 versus ultra low doses (&gt; 0.25‐1.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 2b. Mean dose of orphenadrine (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 versus standard higher dose (&gt;7.5‐15mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 3. Dystonic reaction (duration unclear) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 versus standard higher dose (&gt; 7.5‐15 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 4. Dyskinesia (duration unclear) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 5. Akathisia (duration unclear) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 6. Prolactin at endpoint (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">DOSES: 1. LOW DOSE (&gt; 1.5 to 3 mg) versus OTHER DOSES</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.47, 1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.31, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. No clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.67, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.75, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. Use of adjunctive medication for sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>238</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.79, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus high dose (&gt; 15‐35 mg/day) ‐ less than 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.70, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 versus high dose (&gt; 15‐35 mg/day) ‐ (2‐10 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.75, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state/behaviour: clinically significant agitation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mental state/behaviour: no psychotic symptoms (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.45, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.45, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 2. Use of any antiparkinsonism drugs (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.45, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 3. Specific adverse effects‐blurred vision (&lt; 2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">DOSES: 2. STANDARD LOWER DOSE (&gt; 3 to 7.5 mg) versus OTHER DOSES</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early (day 1‐2) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus high to very high dose range</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 1. By between 3 and 14 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.26, 1.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.26, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early: 2. By between 2 and 10 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.82, 8.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.31 [0.47, 146.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.45, 1.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.26, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 versus high and very high dose (&gt; 15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.12, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 1. No clinically significant response (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Global state: 2. No clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.57, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 versus high dose (&gt;15‐35mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.86, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [0.80, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Global state: 3. Mean change CGI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.80, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐0.86, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Global state: 4. Use of adjunctive medication for sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Global state: 5. CGI score at endpoint (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Global state: 6. Mean dose of lorazepam (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 versus very high doses (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Mental state/behaviour: 2. Clinically significant agitation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Mental State/behaviour: 3. PANNS general endpoint score (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Mental state/behaviour: 3. PANSS positive endpoint score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 versus low dose (&gt; 1.5‐3 mg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Mental state/behaviour: 4. PANNS negative endpoint score (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Mental state/behaviour: 5. Calgary Depression Rating Scale endpoint score (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 1. Acute dystonia (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Adverse effects: dystonic reaction (duration unclear) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Adverse effects: dyskinesia (duration unclear) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Adverse effects: akathisia (duration unclear) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Adverse effects: 2a. Clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [0.49, 9.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.31 [0.47, 146.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 versus high and very high dose (&gt; 15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 4.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Adverse effects: 2b. Mean dose of orphenadrine (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 versus low dose (&gt; 1.5‐3 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Adverse effects: 3. Mean score/change in EPS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Adverse effects: 4. Postural hypotension (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Adverse effects: 6. Prolactin at endpoint (skewed data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 versus low dose (&gt; 1.5‐3 mg/day) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">DOSES: 3. STANDARD HIGHER DOSE (7.5 to 15 mg) versus OTHER DOSES</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.78, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.60, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.68, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: 1. No clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.84, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.48, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.75, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Global state: 2. Mean change CGI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 3a. Use of adjunctive medication for sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.07, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.49, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.67, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 3b. Use of adjunctive medication for sedation (&lt; 2 weeks). <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Global state: 3c. Use of adjunctive medication for sedation (2‐10 weeks). <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mental state/behaviour 1: No psychotic symptoms (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state/behaviour: 2. No clinically important change in psychotic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state/behaviour: 3. Clinically significant agitation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.80, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.49, 2.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.67, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state/behaviour: 4. Mean score ‐ SADS mean score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 1. Clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.29, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.74, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 2. Mean score/change in EPS on Simpson Angus scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐1.41, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 versus very high (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.73, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 3. Use of any antiparkinsonism drugs (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.29, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 versus high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.94, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 4. Akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 versus very high dose (&gt; 35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 3. Specific adverse effects‐blurred vision (&lt; 2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">DOSES: 4. HIGH DOSE (&gt; 15 to 35 mg/day) versus OTHER DOSES</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Death (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Leaving the study early: 1. By between 3 and 14 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.51, 3.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [0.51, 3.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Leaving the study early: 2. By between 2 and 10 weeks <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.62, 3.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>74</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [0.67, 3.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.63, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Global state: 1. No clinically significant response (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Global state: 2. No clinically significant response (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.49, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>255</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.89, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Global state: 3. Mean change CGI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.06, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.40, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Global state: 4. Use of adjunctive medication for sedation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.31, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.59, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Mental state/behaviour: 1. No clinically significant response in psychotic symptoms (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 versus standard higher doses (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mental state/behaviour: 2. No clinically important change in psychotic symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Mental state/behaviour: 3. Mean score SADS mean score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Mental state/behaviour: 4. Clinically significant agitation (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.7 [0.31, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.59, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Adverse effects: 1. Acute dystonia (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Adverse effects: 2. Clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.91, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.70, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Adverse effects: 3. Mean score/change in EPS Simpson Angus Scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Adverse effects: 4. Use of any antiparkinsonism drugs (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 versus standard lower dose (&gt; 3‐7.5 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.81, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.74, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Adverse effects: 5. Akathisia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 versus high dose (&gt; 15‐35 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Adverse effects: 6. Postural hypotension (3 days‐2 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 versus standard higher dose (&gt; 7.5‐15 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">DOSES: 5. VERY HIGH DOSE (&gt; 35 mg/day) versus OTHER DOSES</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">DOSES: 6. HIGH AND VERY HIGH DOSES (&gt; 15 mg/day) versus OTHER DOSES</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 versus standard higher dose (&gt; 7.5‐15 mg/day) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.58 [0.42, 6.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Leaving the study early (day 1‐2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.01, 8.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Leaving the study early (2‐10 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [0.36, 19.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Adverse effects: clinically significant EPSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.25 [0.17, 29.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">DOSES: 6. HIGH AND VERY HIGH DOSES (&gt; 15 mg/day) versus OTHER DOSES</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus medium plasma levels (&gt; 7.0‐16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.35, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus high plasma levels (&gt; 16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.39, 2.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus medium plasma levels (&gt; 7.0‐16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: clinically significant response in mental state, positive symptoms (unclear duration) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus medium plasma levels (&gt; 7.0‐16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus medium plasma levels (&gt; 7.0‐16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.48, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 versus high plasma levels (&gt; 16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.51, 1.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">PLASMA LEVELS: 1. VERY LOW LEVELS (&gt; 1.4 to 3.5 ng/mL) versus OTHER PLASMA LEVELS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus very low plasma levels (&gt; 1.4‐3.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [0.95, 2.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus high plasma levels (&gt; 16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.58, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: no clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus very low plasma levels (&gt; 1.4‐3.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 versus high plasma levels (16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: clinically significant response in mental state, positive symptoms (duration unclear) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus very low plasma levels (&gt; 1.4‐3.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.51, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 versus very low levels (&gt; 1.4‐3.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.21, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 versus high plasma levels (&gt; 16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.89, 1.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">PLASMA LEVELS: 2. MEDIUM LEVELS (&gt; 7.0 to 16.5 ng/mL) versus OTHER PLASMA LEVELS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001951-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 versus very low plasma levels (&gt; 1.40‐3.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.42, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 versus medium plasma levels (&gt; 7.0‐16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.48, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Global state: no clinically significant response in global state (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 versus medium plasma levels (&gt; 7.0‐16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects: clinically significant extrapyramidal side effects (2‐10 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 versus very low plasma level (&gt; 1.40‐3.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.81, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 versus medium plasma level (&gt; 7.0‐16.5 ng/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.54, 1.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">PLASMA LEVELS: 3. HIGH LEVELS (&gt; 16.5 ng/mL) versus OTHER PLASMA LEVELS</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001951.pub2/references#CD001951-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001951.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001951-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001951-note-0004">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001951\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001951\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001951\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001951\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001951\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=jxlIh5Me&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001951.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001951.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001951.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001951.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001951.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729596997"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001951.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729597010"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001951.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ee0bbbc289377',t:'MTc0MDcyOTU5Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 